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Abstract
Microarray gene expression profiling has led to a proliferation of statistical learning
methods proposed for a variety of problems related to biological and clinical discoveries.
One major problem is to identify gene expression-based biological markers for class discov-
ery and prediction of complex diseases such as cancer. For example, expression patterns
of genes are discovered to be associated with phenotypes (e.g., classes of disease) through
statistical learning models. Early hopes that well-developed methods such as support
vector machines would completely revolutionize the field have been moderated by the
difficulties of analyzing microarray data. Hence, new and effective approaches need to be
developed to address some common limitations encountered by current methods. This
thesis is focused on improving statistical learning on microarray data through rank-based
methodologies. The relative expression analysis introduced in Chapter 1 is the central
concept for methodological development where the relative expression ordering (i.e., the
relative ranks of expression levels) of genes is investigated instead of analyzing the actual
expression values of individual genes. Supervised learning problems are studied where
classification models are built for differentiating disease states. An unsupervised learn-
ing task is also examined in which subclasses are discovered by cluster analysis at the
molecular level. Both types of problems under study consist of multiple classes.
In Chapter 2, a novel rank-based classifier named Top Scoring Set (TSS) is developed
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for microarray classification of multiple disease states. It generalizes the Top Scoring
Pair (TSP) method for binary classification problems to the multiclass case. Its main
advantage lies in the simplicity and power of its decision rule, which provides transpar-
ent boundaries and allows for potential biological interpretations. Since TSS requires a
dimension reduction in the training process, a greedy search algorithm is proposed to
perform a fast search over the feature space. In addition, ensemble classification based
on TSS is also investigated.
In Chapter 3, an efficient and biologically meaningful dimension reduction for the
TSS classifier is introduced using the publicly available pathway databases. Pre-defined
functional gene groups are analyzed for microarray classification. The pathway-based
TSS classifier is validated on an extremely large cohort of leukemia cancer patients.
Also, the unsupervised learning ability of relative expression analysis is studied and a
rank-based clustering approach is introduced to identify molecularly distinct subtypes
of breast cancer patients. Based on the clustering results, the TSP classifier is used for
predicting the subtypes of individual breast cancer tumors. These rank-based methods
provide an independent validation for the current identification of breast cancer subtypes.
Overall, this thesis provides developments and validations of statistical learning meth-
ods based on relative expression analysis.
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DNA microarray technology was first introduced in the mid-1990s to probe the expres-
sion of thousands of genes simultaneously [68, 72]. This technique was quickly adopted
for the study of a wide range of biological processes. The use of gene expression microar-
ray data initially focused on the identification of differentially expressed genes associated
with human diseases (e.g., asthma, heart disease and cancer) [14,27]. In the last decade,
the application of gene expression microarrays to discover and discriminate subclasses of
human cancer has attracted tremendous interest. Cancers are conventionally classified by
the type of tissue in which the cancer originates. However, the traditional histopathology
of a cancer specimen by experienced doctors is subjective and prone to human error.
Moreover, different cancer subclasses can have similar histopathological appearances but
may differ substantially in terms of therapeutic responses and clinical courses [35]. In
this situation, microarray-based gene expression profiling offers a hope that statistical
analysis tools can be developed to improve the diagnosis and prognosis of cancer.
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Early studies used unsupervised methods such as cluster analysis to identify sub-
groups of patients based on gene expression patterns [2]. Such studies suffered from the
limitation that only samples in large retrospective studies could be classified by unsu-
pervised methods, and results provided little guidance for clinical prognosis of individual
samples. In 1999, Golub et al. [35] pioneered a supervised molecular classification of can-
cer using gene expression profiling. They devised a statistical scheme based on patient
samples having two subtypes of leukemia cancer: acute lymphoblastic leukemia and acute
myeloblastic leukemia. The diagnostic type of each patient was known a priori. They
demonstrated the ability of the scheme to assign appropriate subtype labels for another
independent group of leukemia patient samples. This study received wide attention in
the research community and inspired subsequent studies to search for predictive gene
expression patterns using statistical tools.
As a result, numerous statistical methods were introduced for microarray-based dis-
ease classification. Most of these methods are drawn from other research areas that
require data analysis such as computational vision and natural language processing. In
general, they are so called “machine learning” methods that aim to make a certain kind
of prediction on the new data. In the context of disease classification, a simple example
would be to predict whether or not a particular patient has a certain disease. While
such binary classification problems were widely explored in the scientific literature and
achieved considerable success [55,92], problems that contain multiple classes received rel-
atively less attention [31, 79]. However, as the genetic heterogeneity of complex diseases
such as cancer has been increasingly appreciated in recent studies [8, 75], the discovery
of new disease classes is expected to continue, leading to a growing number of multi-
class problems. Moreover, a large number of experiments for investigating diseases in
2
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stage, survival time and therapeutic response are producing microarray data encompass-
ing multiple classes [9,21]. As a result, there is an increasing need for developing statistical
methods that can handle multiclass problems.
This thesis is focused on addressing the limitations of current machine learning tech-
niques as applied to disease classification of multiclass problems using microarray anal-
ysis. In particular, common issues such as the small-sample learning situation and the
interpretability of classification rules are discussed in detail. In this chapter, the biologi-
cal and statistical background of problems investigated in this thesis are first described.
Then, the motivation and fundamentals to develop new statistical methods for multiclass
problems are presented. Next, an overview of proposed methods and contributions is
provided.
1.2 Microarray Data
A microarray consists of a dense patterning of thousands of cDNA strands or oligonu-
cleotide sequences immobilized on an inert substrate (usually a glass slide or a nylon
membrane). The immobilized sequences are referred to as “probes”. The microarray
technique uses gene-specific probes to detect variations in levels of gene expression in
a target biological sample. As described in [68], Gene expression experiments start by
isolating RNA from tissue of interest and tagging it with a detectable marker (e.g. flu-
orescent dye). The labeled RNA is then washed over the surface of the microarray, and
allowed to incubate for a period of time, during which samples of messenger RNA (mRNA)
hybridize to the target gene probes. Then scanning of the microarray, using either confo-
cal microscopy or phosphor imaging techniques, yields quantifiable digital images of the
array hybridization results. The relative fluorescence intensity of each gene-specific probe
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is a measure of the level of expression of the particular gene. The greater the degree of
hybridization implies a higher relative intensity.
The data collected after scanning consists of intensity readings for each spot on the
array. These intensity readings are typically biased and noisy measurements of gene
expression levels due to systematic and random variations in the microarray experiment,
and they often need to be carefully preprocessed, with different microarray platforms
requiring different preprocessing methods. These methods share three common steps:
background adjustment, normalization and filtering. Background adjustment corrects
for non-specific hybridization and noise in the optical detection system. Normalization
aims to facilitate the comparison between different arrays. It compensates for variations
such as efficiencies of labeling, hybridization reactions, array differences and laboratory
conditions. Additionally, the data are often filtered to exclude genes that show limited
variation or relatively low intensity in expression levels across all biologic samples. In
general, there are a variety of statistical analysis methods proposed for preprocessing
micrarrays in the literature [44, 68].
After preprocessing, the data are usually transformed into a matrix of expression
values. Each row of the matrix contains the expression values of a gene and each column
represents a specific biological sample. The expression values are positively correlated
with the intensity readings so that a relative large value indicates the gene is highly
expressed compared to other genes. However, there are no apparent patterns that can
be immediately identified to associate with any group of samples. In fact, the expression
matrix often contains tens of thousands of genes but only up to hundreds of samples.
Most genes seem to provide noisy and inconsistent signals across all samples, and it is
extremely difficult to study all genes as a whole given the gene interdependencies and
4
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the small sample size available. Therefore, a routine analysis is to find genes that show
patterns of expression correlated with disease states. Such groups of genes are typically
referred to as “gene signatures” where their diagnostic and prognostic value are assessed
for a variety of clinical applications.
1.3 Statistical Background
Biological insights for various diseases can be gained by exploring microarray data.
In particular, many problems of studying diseases appear in the form of “supervised
learning”. In a general supervised learning problem, there is often a set of variables that
are measured as inputs and they will have some influence on one or more outputs. For-
mally, the inputs are often called features, and depending on the type of the problem,
the outputs are referred to as class variables in classification or responses in regression
analysis. For either case, the purpose is to use the features to predict the values of the
outputs. In the context of supervised classification, the features are the expression levels
for the set of genes from microarray data, and the class variable takes categorical values
representing different patient groups identified based on prior knowledge or different out-
comes of clinical trials. Since the purpose of classification is always to establish a rule
that can be used for prediction, these two terms (“classification” and “prediction”) are
used interchangeably throughout the thesis. Here, the classic Bayesian decision theory
is first presented to provide a framework for developing statistical models used in super-
vised classification. Then an important concept is discussed related to the assessment of




Let X ∈ Rp denote an ordered set of real valued random variables, and Y a discrete
random variable. In particular, X is a p−dimensional random vector consisting of features
and Y is the corresponding class variable. The goal is to seek a function f(X) to predict
Y given the values of variables in X. Typically L = {(x1, y1), (x2, y2), ..., (xN , yN)} rep-
resents a set of N training samples observed before hand on which a classifier/predictor
f̂(X) is trained. Therefore, each observed x of X makes a prediction of its class label as
f̂(x). In theory, a loss function l(f̂(X), Y ) is required here for penalizing misclassification
errors. A commonly used loss function in classification is the 0-1 loss
l(f̂(x), y) = I{f̂(x)6=y},
which assigns one unit of loss for each misclassification. After specifying a loss function,
an key quantity of interest is the error incurred in prediction, also referred to as the
“generalization error”, which is the expected loss over a set of samples independent of
those used for training
E[l(f̂(X), Y )],
where both X and Y are drawn from their joint probability distribution P (X, Y ). In this




To obtain f̃ , it suffices to consider the minimum of the error at each point x
f̃ = argmin
f̂
E[l(f̂(X), Y )|X = x].
6
CHAPTER 1. INTRODUCTION












I{ŷ 6=k} · P (k|X = x)
= argmin
ŷ∈{1,2,...,K}
1− P (ŷ|X = x)
= argmax
ŷ∈{1,2,...,K}
P (ŷ|X = x).
This optimal solution is often known as the “Bayes rule”, and it concludes that the best
prediction for Y is the class that maximizes the posterior distribution given X. This
rule is also commonly referred to as maximum a posteriori. In practice, this posterior
distribution is often unknown and has to be estimated from the data. According to Bayes’
theorem,






P (y|X) = argmax
y
P (X|y)P (y).
Thus, an alternative solution is to estimate P (X|Y ) and P (Y ), the class conditional
densities and the prior distribution of the class variable.
The decision theory discussed above serves as the foundation from which many clas-
sification methods are derived for modeling either P (X|Y ) (P (Y ) often estimated as the
observed frequencies or simply equal priors) or P (Y |X). For the former case, a clas-
sic example is the linear discriminant analysis classifier that assumes each class density
P (X|Y = k) is a p-dimensional multivariate Gaussian distribution N (µk,Σk) where the
Σk takes a common value Σ, for all k. Another example is the naive Bayes classifier, which
makes a simplified assumption that each of the conditional class densities are products
of marginal densities of features. For the Gaussian naive Bayes classifier, each marginal
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density is assumed to be Gaussian, and in this case P (X|Y = k) turns out to be a product
of many one dimensional Gaussian densities. On the other hand, there exist a number of
methods that aim to model P (Y |X) directly, and the k-nearest-neighbor classifier is one
of them. In this method, the posterior probabilities at one point P (Y |X = x) are actu-
ally relaxed to posterior probabilities within a neighborhood of a point P (Y |X ∈ Nk(x)),
which are empirically estimated by training-sample proportions. The logistic regression
classifier is another example. It arises from the motivation to model the log-odds ratios
of posterior probabilities as linear functions of x given by
log
P (Y = k|X = x)
P (Y = K|X = x) = αk + β
T
k x k = 1, 2, ..., K − 1,
where αk ∈ R and βk ∈ Rp are model parameters. Then a simple calculation shows that





i=1 exp(αi + β
T
i x)
, k = 1, 2, ..., K − 1,
P (Y = K|X = x) = 1
1 +
∑K−1




Therefore, these posterior probabilities are immediately available given the estimates
of model parameters.
In general, after approximating P (X|Y ) or P (Y |X) from the data, the Bayes rule can
be constructed for classification. However, this empirical rule may no longer be optimal
due to the assumptions made for modeling either P (X|Y ) or P (Y |X). Thus, the quality
of a particular classification model can depend on how well the model assumptions fit
the data. However, even if the model is correct, the calibration of the model can still be
limited by the sample size available. Regardless of the sample size issue, the misspecified
model assumptions can pose severe limitations on many classification models because the
microarray data typically follow complex and unknown distributions that are likely to
violate the assumptions of these models. In this situation, classifiers that do not rely on
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the theory described above may produce an improved performance. In fact, there exists
a collection of methods called “discriminative” methods that do not rely on estimates for
either P (X|Y ) or P (Y |X). Instead, they directly focus on identifying effective decision
boundaries of different classes. Probably the most popular discriminative method is
support vector machine (SVM) [11]. SVM originates from the perceptron classifier [74]
developed in the late 1950s that constructs a hyperplane via a linear combination of the
input features to separate two different classes, and the hyperplane is found by minimizing
some target function related to misclassification. In contrast, SVM usually produces
nonlinear boundaries by constructing a linear boundary in a large, transformed version
of the feature space. Therefore, SVM provides a large degree of flexibility and can handle
difficult classification problems.
1.3.2 Bias-Variance Tradeoff
Each of the classification approaches described above has a certain level of complex-
ity. Different approaches may have different levels of complexity because they are based
on different underlying theories and they differ in the type and number of parameters.
The complexity of an approach generally affects its predictive performance. For example,
nonlinear classifiers may be more powerful than linear classifiers for a classification prob-
lem that has complex decision boundaries. In this sense, it is plausible that a model’s
performance can be improved by increasing complexity. However, as explained by the
tradeoff between bias and variance described below, this is not always the case.
As in the previous section, the goal is to find a function f(X) to predict Y . The focus
is to analyze the generalization error incurred, which can depend on the choice of loss
9
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functions. The generalization error of prediction has the form of
E[l(f̂(X), Y )]
where f̂ is the classification model estimated from the training data. Note that this
expectation is averaged over the training data that produce f̂ . Assume Ŷ = f̂(X) and
Y ∈ {1, 2, ..., K}, the bias-variance decomposition of E[l(Ŷ , Y )] for the quadratic loss
function is actually well known, e.g., see [42] and serves as an important tool for ana-
lyzing learning algorithms. For classification problems where the 0-1 loss function is a
common choice, the bias-variance decomposition of E[l(Ŷ , Y )] has also been carefully in-
vestigated, e.g., see Dietterich and Kong [19], Breiman [6] and Kohavi and Wolpert [51].
Regardless of the detailed mathematical descriptions in these studies, the generalization
error typically has three components: σ2, Bias2 and Variance. The σ2 term is sometimes
called “irreducible error” because it is inherently caused by the target Y and is indepen-
dent of the learning algorithm. Thus, the quantities of interest are often the “Bias2” and
the “Variance” term. For the quadratic loss function, the “Bias2” term represents the
error incurred due to the limited capacity of the model family to approximate the true
relation between Y and X, and the “Variance” term explains the error caused by estimat-
ing the model from the training data. As mentioned above, these terms are also shared
by the 0-1 loss function, but may have different explanations. According to [51], the
“Bias2” term measures the squared difference between the target Y and the algorithm’s
output Ŷ averaged over all possible training sets, and the ”Variance” term measures how
sensitive the algorithm is to the changes in the training set. The variance reaches the
minimum value zero if the learning algorithm always makes the same guess regardless of
the training set. Regardless of the type of the loss function, the model complexity links
the bias and the variance terms by introducing a tradeoff between them. As the model
10
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complexity is increased, the bias tends to decrease, but typically the variance increases.
For example, a complex model may have a complex decision boundary that adapts bet-
ter than a simple model to the probability change of the target Y for different sample
points, but the complexity of the model may result in sensitivity to the change in the
training data and cause an increase of the variance, which leads to so called “over-fitting”
problem.
For problems considered in this thesis, “small n, large p” is a common situation. Here
n refers to the number of training samples and p represents the number of features, or
specifically, genes. In this case, supervised learning is a formidable task because the high-
dimensional data requires complex models while the small sample size demands simple
models. This “small n, large p” dilemma widely exists in problems of computational
biology where many traditional statistical methods derived from other fields often break
down. In particular, these methods are generally designed for producing accurate predic-
tions under the assumption that there are “enough” training samples, a condition that
holds in many other fields such as image analysis or natural language processing. How-
ever, learning from biological data based on these methods is likely to cause over-fitting.
The small training-sample size barely provides good estimates of the model parameters,
which can be subject to large variances. Hence, in view of the bias-variance tradeoff,
the variance term here plays a much more important role, and it is necessary to restrict
the model complexity. A possible strategy is to develop simple models based on plausi-




1.4 Relative Expression Analysis
The main challenge for microarray-based classification is to develop techniques that
yield relatively accurate and robust decision rules. Since gene expression measurements
largely depend on microarray experiments, microarray-based statistical inference can be
affected by a number of factors, such as experimental design and the type of data nor-
malization. Therefore, traditional techniques in statistical analysis may need to be re-
designed to address these issues. Also, there is always value added if a particular decision
rule can be interpreted with respect to the biology of the underlying disease. Interpretabil-
ity facilitates follow-up studies for biological validation, which may eventually lead to the
development of clinical applications. However, many advanced classification techniques
such as support vector machines [11], random forest [7] and neural networks [49] are de-
rived for general purpose classification where accuracy is the top priority. Such models
can be viewed as “black boxes” where the decision process is hidden and can be quite
complex, and their decision rules do not lend easily to biological mechanistic understand-
ing.
For complex diseases, the phenomenon of interactions among multiple genes and other
molecular agents within biological networks can be expected to be considerable. Genes
in networks connect and operate in a combinatorial manner. Hence the information
gleaned from the expression patterns of individual genes may only serve as references for
each other and become biologically meaningful only in a relative comparison. Recently,
methods for analyzing microarray data based on biologically meaningful pathways or
networks have achieved considerable success [32, 50, 84]. These frameworks have been
applied to diverse cancer systems and serve as a robust source of biological discovery.
One way to probe the interactions among genes is to study the relative ordering
12
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(ranks) of their expression values. In microarray experiment, expression values within a
sample are assayed simultaneously, and the relative ordering of expression can be more
reliable and robust than raw values: it is likely to be preserved under slight perturbations
of gene expression values and are robust against any effect that shifts expression values
in the same direction. Lin [90] showed that the relative ordering is invariant under
commonly used preprocessing techniques such as convolution and quantile normalization
in RMA [44].
The idea of using relative ordering was proposed by Geman et al. [33] in which the ex-
pression values of two genes were compared for distinguishing two phenotypes of interest.
A rank-based classification approach, named “Top Scoring Pair”(TSP), provided trans-
parent but powerful decision rules which were shown to compete with many sophisticated
machine learning approaches. In subsequent studies, TSP has been extended in a number
of ways. Xu et al. [89] considered the average ranks in two groups of genes (rather than
a pair of genes) for constructing the decision rule. Tan et al. [83] introduced the k-TSP
classifier where the top k scoring pairs (i.e., gene pairs with top k scores) were involved
using the majority rule in the decision process. Also, Lin et al. [56] proposed the “Top
Scoring Triplet” method in which relative ordering in each triplet (i.e., three genes) were
investigated using a similar approach in TSP. Recently, Kaur et al. [47] introduced the
“ProtPair” method that used TSP for human disease prognosis based on protein expres-
sion data. Such rank-based methods are described as forms of what is termed “Relative
Expression Analysis” in [23].
In principal, relative expression analysis investigates the combinatorial patterns asso-
ciated with a group of genes. Probability distributions of different combinatorial expres-
sion orderings are often estimated for small-sized gene sets and statistical significance is
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assessed based on estimates. The ordering of expression values is obtained within each
sample and no cross-sample comparisons are considered. Although such a comparison
may not represent the actual mechanisms of complex diseases, it is likely to be linked with
biological activities such as regulation of gene expression. In fact, given the amount of
data typically available for microarray analysis, the empirical distribution of the ordering
of expression values for a small collection of genes seems to be one of the few types of
statistics that can be robustly estimated. Overall, relative expression analysis methods
provide simplified models to study genetic networks and can potentially offer insights into
biological mechanisms.
1.5 Proposed Methodology
This thesis focuses on developing rank-based methods for statistical learning prob-
lems arising in gene expression analysis. In particular, methods are derived to improve
microarray-based classification in the presence of multiple classes. The discriminative
power of small-sized gene sets among phenotypes are explored where the relative expres-
sion in each gene set is the focus rather than the actual values.
The first attempt is to extend the TSP method in the multiclass setting. Previous
extensions discussed in the last section are all focused on binary problems. In the multi-
class case, the “small n, large p” problem is especially compounded when subdivision of
an already small set of samples into subclasses leads to dramatically smaller sample sizes
for subclasses. Also, multiclass methods typically require significantly more computation,
and decision rules generated can become more complex. To address these issues, the “Top
Scoring Set” method is proposed to generalize the idea of relative comparison in TSP. For
an m-class problem, TSS searches for a number of m-gene sets to make class predictions.
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Each selected set (i.e., top scoring set) tends to preserve a distinct ordering of its member
genes in a single class, which is considered as the signal for class discrimination.
The second attempt focuses on discovering similarity of samples based on relative
ordering of their expression values. In particular, a rank-based clustering approach is
considered that uses the Kendall’s rank coefficient [48] as the distance measure for any
pair of samples. After the distance matrix is calculated, the traditional hierarchical
cluster analysis is applied. This approach aims to quantify the differences among classes
by investigating combinatorial behaviors of gene pairs, and can also be combined with
supervised classification methods.
At the same time, attempts have also been made to develop techniques to improve the
efficiency of training classification methods proposed in the thesis. Although conventional
feature selection methods such as one-way ANOVA or Kruskal-Wallis, its non-parametric
analog can be used, it is better to have techniques particularly suited to microarray data
and problems under study. In this thesis, two such approaches have been developed. The
first one applies a greedy search algorithm on the expression values of individual genes.
The second one tries to incorporate biological knowledge when pathway information can
be inferred from the gene expression data.
1.6 Summary of Contributions
In summary, this thesis brings forth the following research developments:
1. Development of a new approach for microarray-based classification of multiclass
problems mainly related to cancer. The approach naturally handles multiclass
microarray data and acquires some nice properties such as parameter-free-ness and
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invariance under several common preprocessing techniques. The decision rule is
transparent and easy to interpret. This classification approach has been validated
on seven microarray gene expression data of human cancers including leukemia,
lung and bladder cancer. Its robustness has been demonstrated on an extremely
large cohort of leukemia cancer patients and a cross-center cohort of bladder cancer
patients. In addition, the potential of the approach to combine ensemble techniques
such as boosting has also been explored.
2. Proposal of two methods to improve the efficiency of training the classification
approaches introduced above. The first method uses a greedy search algorithm
to quickly screen the entire set of genes to search for discriminative expression
patterns. The second one relies on pre-defined gene groups from public databases
such as pathways to restrict the search. These two methods are tested on a variety
of microarray data sets.
3. Proposal of a rank-based clustering method used for unsupervised learning tasks
with respect to microarray analysis. The method explores a group of pre-selected
genes that are potentially related to phenotypes of interest, and constructs a dis-
tance matrix for samples based on the Kendall’s rank coefficient. Hierarchical clus-
ter analysis is then built upon the distance matrix. This method is validated using
a compendium of three breast cancer data sets where it is applied to identify dis-
tinct subtypes for analyzing patient survival time. The prognostic value of these
identified subtypes is compared to published expression-based models and gene sig-
natures.
In general, this thesis focuses on a variety of multiclass problems with respect to gene
expression analysis. It demonstrates the importance of tailoring statistical learning
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methods to microarray classification and the usefulness of developing methodologies





The study of complex diseases such as cancer via microarray analysis is producing an
ever-growing set of multiclass classification problems. As limitations (e.g., reproducibility
and interpretability) of traditional machine learning techniques have been increasingly ap-
preciated, new and effective methodologies are expected to be developed to address these
problems. In this chapter, the “Top Scoring Set” (TSS) approach [91] is developed for
classification of microarray data containing multiple classes. The background of mul-
ticlass classification in microarray analysis is first introduced. Then the TSS classifier
is described and discussed in detail, followed by two validation studies. Lastly, some
theoretical developments of TSS are presented.
2.1.1 Multiclass Methods
The literature on microarray-based classification methods is extensive, see, e.g., the
review by Pirooznia et al. [66]. Some discussions of multiclass classification methods for
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gene expression analysis have been provided by Statnikov et al. [79] and Tao et al. [55].
These multiclass approaches can be roughly divided into direct and indirect approaches.
Direct approaches can immediately apply to multiclass problems, while indirect ones
rely on schemes such as “one-vs-one” [30] or “one-vs-all” [74] to decompose a particular
multiclass problem into a set of binary problems. Thus, indirect approaches tend to
be more computationally intensive because they aim to solve an ensemble of simpler
problems.
The most straightforward direct approach is k-Nearest-Neighbor (kNN). The main
idea of kNN is based on the concept of similarity. The distance between the test sample
whose class is to be decided and each of the training samples is computed using a certain
metric (e.g., Euclidean distance). To predict a test sample, kNN uses the class labels of the
k closest samples in distance from the training set and takes a majority vote. Therefore,
kNN can naturally handle multiple classes and hence often serves as a benchmark method
in many studies [55,83,92]. It also has been proven that the error of kNN is asymptotically
at most two times the optimal Bayesian error [18].
Another commonly used direct approach is Naive Bayes (NB). NB assumes that given
any class, the distributions of features are independent from each other. As a result, it
expresses the multivariate conditional distribution of features given the class as a prod-
uct of the conditional distributions of the individual features. Hence, NB only requires
estimation of a number of parameters that is linear in the dimension of feature space.
Although this assumption is often violated in practice, it has at least two advantages.
First, it is quite computationally efficient for high-dimensional microarray data, and sec-
ond, it reduces variance error by possibly creating bias error, though the bias error may
be arbitrarily large. The “naive” assumption also allows for explicit derivation of the
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Bayes rule for class prediction, and this rule can be applied immediately to any number
of classes.
Linear discriminant analysis (LDA) and its variants constitute another classic family
of direct methods. Typically they assume the class conditional distributions as multivari-
ate Gaussian where class-wise mean values differ but class-wise covariance matrices are
the same. For microarray classification, LDA is greatly challenged by the “small n, large
p” problem due to the number of correlations among features to be determined versus
the size of available samples. Therefore in practice, either a small set of features has to
be selected prior to classifier training or some variants of LDA such as diagonal LDA
are considered. A good improvement of LDA as applied to gene expression analysis is
proposed by Tibshirani et al. [85]. The method is known as “Prediction Analysis of Mi-
croarray” (PAM). It eliminates the effect of many noisy genes in traditional discriminant
analysis by shrinking their values towards the class centroids, i.e., the mean expression
values of classes. As a result, PAM uses relatively few genes for classification, which is
quite favorable for understanding the underlying biology.
Decision trees (DT) are also commonly used for multiclass problems. An early imple-
mentation of decision trees, known as CART (Classification and Regression Tree), used
binary decisions. A popular later development is C4.5 tree by Quinlan [69]. DT sequen-
tially selects important features as split points and reaches its decision as adequate splits
are made. The choice of split points is often based on concepts of information theory
such as entropy. For applying DT on microarray data, one main advantage is that it
offers an interpretable decision rule that consists of “if...else...” rules when tracing the
tree from top to bottom. The normal decision tree can grow to a large size and it is often
pruned to control the computational cost and to address over-fitting. But the pruned
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tree only utilizes a small set of features and the model bias can be large. This limitation
is addressed by “random forests” (RF) [7], an ensemble classification method that oper-
ates by constructing multiple decision trees based on random choices of features on the
training data. The final class prediction is the mode of the classes output by individual
trees. The power of RF has been demonstrated in many studies [53, 80].
Support vector machines (SVMs) [11] are perhaps the single most important develop-
ment in supervised classification. They have been proved to obtain superior classification
performance compared to other methods in many domains and tasks, and they can handle
large-scale classification in both samples and variables. In particular for gene expression
analysis, their powerful performance has been demonstrated in various studies [62, 80].
SVMs originate from optimal hyperplane classifiers such as perceptrons [70]. Samples
in the original space are projected onto a higher dimensional feature space where they
can be well separated by a maximal margin hyperplane (the margin is the distance be-
tween the hyperplane and the sample closest to it), which can be found by solving an
optimization problem. SVMs were initially designed for binary classification problems,
and there are two major approaches to extend them in the multiclass setting. The first
approach is to use decomposition schemes mentioned above to reduce the problem into a
set of binary sub-classification problems, which are solved individually and their decisions
lead to the final decision based on a majority vote. The second approach is to modify
the original (binary) optimization equation into a multiclass objective function [12, 43].
These methods are often referred to as multiclass SVMs.
Unlike direct approaches, indirect approaches require the decomposition of a mul-
ticlass problem into binary ones. “One-vs-all” is a popular scheme that decomposes a
K-class problem into a set of K sub-problems, each of which is a binary problem. To be
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precise, for class i = 1, 2, ..., K, a classifier is constructed to distinguish between i and
{1, 2, ..., i−1, i+1, ..., K}. The final decision for class prediction is the class that receives
the most votes from these K classifiers. As discussed before, another commonly used
scheme is “one-vs-one” and is also known as pairwise coupling. In this case, for every
distinct pair of classes i and j, i, j ∈ {1, 2, ...K}, i 6= j, a binary classifier is trained using
samples from those two classes. As a result, K(K−1)
2
classifiers are constructed, each of
which votes for a single class. The final decision again is the class that gets the most
votes.
In summary, this section provides an extensive list that covers most of the current
multiclass methods, many of which serve as benchmark methods in this thesis.
2.1.2 Related Work
Supervised classification problems based on microarray analysis have been investigated
for years. Standard methods in areas such as machine learning and pattern recognition
are routinely applied to microarray data, including neural networks [49], decision trees
and support vector machines [80]. But the learning abilities of these state-of-the-art
techniques are often limited due to the “small n, large p” dilemma. In view of the bias
and variance trade-off, simplifying assumptions and special designs appear necessary.
One of the approaches attempting to address these limitations was proposed by Geman
et al. [33]. They introduced the “Top Scoring Pair” (TSP) method as a new binary
classification approach by simply comparing expression levels in one or more pairs of genes
(i.e., top scoring pairs) to make a classification decision. As illustrated in Figure 2.1, the
expression levels of gene SPTAN1 and CD33 are displayed for 72 patient samples from
[35], which are grouped according to two types of leukemia cancer: acute myeloid leukemia
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(AML) and acute lymphoblastic leukemia (ALL), with 25 and 47 samples respectively.
TSP classifies a sample as ALL if SPTAN1 has higher expression level than that of CD33
in the sample, and AML otherwise. Although this decision rule seems simple, it was
demonstrated to compete with a number of sophisticated machine learning approaches.
In addition, gene pairs selected by TSP in various subsequent studies were found to be
biologically informative, see, e.g., [24], [94] and [63].






























Figure 2.1: Gene expression patterns for a top scoring pair of genes.
The TSS approach developed in this chapter is motivated by TSP and is essentially a
generalization of TSP in the multiclass case. For an m-class problem, the class prediction
is determined by a relatively small number of m-gene sets, namely, top scoring sets. Each
top scoring set votes for a class based on the ordering of expression levels of its genes.
The final prediction is the class that receives the majority of votes. In principle, TSS
makes specific statistical hypotheses about gene expression comparisons that could have
biologic interpretations, and even without the potential interpretability, the decision rule
itself can be easily appreciated by non-specialists.
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There is no question that some gene expression patterns that are potentially useful
for classification may be dismissed by TSS, and the assumption made in TSS might seem
insufficient to reflect biological conditions in complex diseases. However, TSS provides a
practical attempt for modeling the statistical dependency structure among genes given
the amount of data, and results achieved in this chapter demonstrate that the information
in the ordering of gene expressions is sufficient to reliably perform classification.
2.2 Methods
Consider G genes measured using DNA microarrays and their expression levels X =
{X1, X2, ..., XG} regarded as a random vector. Each observed gene profile x is a realization
of X and has a true label y representing its class. A microarray data set is a collection
of many, say N, observed gene profiles and can be represented as a matrix {xij} with G
rows of genes and N columns of samples (typically G ≫ N). This section begins with a
brief introduction of the TSP method. Then the “Top Scoring Set” classifier is developed
as a new approach by generalizing TSP in the multiclass setting.
2.2.1 A short review of TSP
As discussed in [33], for a two-class problem (with classes denoted by 1 and 2), TSP
aims to find each “marker” gene pair (i, j) (i, j ∈ {1, 2, ..., G}) that has a simple relation
whose probability distribution changes significantly from one class to the other. The
simple relation considered here is the comparison between the expression levels of gene i
and j, and a highly relevant quantity of interest is P (Xi > Xj | y) where y is the class
variable, y ∈ {1, 2}. So if P (Xi > Xj | y = 1) is high while P (Xi > Xj | y = 2) is low, it
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will be very likely to observe Xi > Xj in class 1 but not in class 2 where Xi < Xj is more
likely to happen. As a result, this property of (i, j) leads to the ability to distinguish
between two classes simply by determining the gene having the higher expression value,
a simple decision rule for predicting class labels. In TSP, a score is defined for each
distinct gene pair (i, j) as |P̂ (Xi > Xj | y = 1) − P̂ (Xi > Xj | y = 2)| in order to
estimate the probability change from class to class where P̂ (Xi > Xj | y) is the frequency
observed from the data. Those that achieve the highest score among all possible gene
pairs (i.e., top scoring pairs) are involved in the decision rule. For a top scoring pair that












class 1, if xi > xj,
class 2, if xi < xj.
(2.2.1)
Then the predictions for each class are summed up and the majority rule is applied to
produce the final prediction. The decision rule of TSP is only based on simple comparisons
of gene pairs. However, it has been shown as an effective classifier on many cancer data
sets, and some top gene pairs from these studies have been found to be informative. Also,
TSP has been extended in a number of ways. Xu et al. [89] considered the average ranks
in two groups of genes (rather than a pair of genes) for constructing the decision rule.
Tan et al. [83] introduced the k-TSP classifier where the top k scoring pairs are involved
using the majority rule in the decision process. Also, Lin et al. [57] proposed the “Top
Scoring Triplet” method in which relative orderings in each triplet (i.e., three genes)
are investigated using a similar approach in TSP. Recently, Kaur et al. [47] introduced
the “ProtPair” method that uses TSP for human disease prognosis based on protein
expression data. All of these derivations have been for binary problems so far.
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2.2.2 Top Scoring Set
This section introduces TSS as a new multiclass classification approach. The mo-
tivation of TSS comes from the relative comparison idea used in TSP. As discussed
in [33], relative comparison of mRNA concentrations indicated by gene expression levels
provides a natural link with biochemical activity, and proposes concrete hypotheses for
a small list of genes. Therefore, the goal here is to discover valuable information for
separating multiple classes by comparing expression patterns of a few genes. In par-
ticular, for an m-class problem (with classes denoted by 1,2,...,m), m “marker” genes
S = {i1, i2, ..., im} ⊂ {1, 2..., G} are found in which the presence of some simple relations
among these genes with high conditional probability depending on the class leads to class
separability. Specifically, the high expression level of gene ic relative to the other m− 1
genes in S is assumed to be strongly indicative of a sample coming from class c. To be
precise, the desired statistical property for S is that ∀c ∈ {1, 2, ...,m}
P [argmax{Xr, r ∈ S} = ic | y = c] ≫ P [argmax{Xr, r ∈ S} = ic | y 6= c]. (2.2.2)
In other words, gene ic is much more likely to be the gene that has the maximum
expression level in S for class c than for any other class. In this case, a classification
rule can be constructed by determining which gene is most expressed in S with a simple
“max” function. Therefore, it is essential to find gene sets satisfying (2.2.2) with the
greatest possibility for discrimination. For this purpose, a score is defined for each m-
gene set to estimate its probability of holding (2.2.2). The sets with the highest score are
hence referred to as the top scoring sets and are used for classification.
An example of a TSS classifier is illustrated in Figure 2.2. Here a more difficult task
than that in Figure 2.1 is considered to distinguish three subtypes of the leukemia data
from [35]. Three leukemia subtypes are AML, B-ALL (B-cell ALL) and T-ALL (T-cell
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Figure 2.2: Gene expression pattern for a top scoring set.
ALL), with 25, 38 and 9 samples respectively. Figure 2.2 depicts a top scoring set that has
been found consisting of gene PLCB2, MB-1 and LCK. Class prediction for a particular
sample is determined by the gene whose expression level in this set is the highest. As
shown later, TSS yields 95.83% prediction accuracy on this data set using leave-one-out
cross-validation.
In general, TSS searches for gene sets exhibiting a particular pattern that may be
suitable for classification. There are, of course, many other patterns that one might
consider with the potential for effective classification. Still, it is important to be mindful
that increasing the size of the pattern search space would result in increases in already
substantial computational costs, and is more likely to produce over-fitting.
Gene set score
To illustrate the scoring method, the example in Figure 2.2 is considered, and the goal
is to score the gene set consisting of PLCB2, MB-1 and LCK. Denote three genes as i1,
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i2 and i3 respectively, and the observed class conditional frequencies of their expression
comparisons can be calculated in Table 2.1.
Table 2.1: Observed frequencies of expression comparison for a three-gene set.
Leukemia
AML B-ALL T-ALL
Xi1 > max(Xi2 , Xi3) 1 0 0
Xi2 > max(Xi1 , Xi3) 0 0.9737 0
Xi3 > max(Xi1 , Xi2) 0 0.0263 1
Interestingly, for AML, gene i1 has the highest expression level among three genes in
100% of the samples, as indicated by the first column of Table 2.1. Similarly, for B-ALL,
gene i2 has the highest expression level in 97.4% of the samples, and for T-ALL gene i3 has
the highest expression level for 100% of the samples. Therefore, based on the information
provided by these three genes, a natural way to classify a sample with expression levels
x, would be to predict AML, B-ALL, and T-ALL respectively by determining which of
the three expression levels xi1 , xi2 , and xi3 is highest. Accordingly, we define a score for
{i1, i2, i3} based on Table 2.1 as the sum of the row maxima, i.e.
max{1, 0, 0}+max{0, 0.9737, 0}+max{0, 0.0263, 1} = 2.9737.
If the score is 3, clearly, the rule described above obtains a zero apparent error rate on
the data set. Furthermore, if the underlying probability distributions of gene expression
comparisons are well reflected by the observed frequencies, a higher score indicates that
the rule is more likely to be effective for new samples. Therefore, the ultimate goal is to
search for three-gene sets with the highest possible score.
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In general, for an m-class problem, each m-gene set S = {i1, i2, ..., im} leads to a
similar table as follows
Table 2.2: Observed frequencies of expression comparison associated with S.
Class
y = 1 y = 2 ... y = m
Xi1 > max{Xr, r ∈ S \ i1} p̂11 p̂12 ... p̂1m
Xi2 > max{Xr, r ∈ S \ i2} p̂21 p̂22 ... p̂2m
...... ......
Xim > max{Xr, r ∈ S \ im} p̂m1 p̂m2 ... p̂mm
where p̂rj is the frequency that given class y = j, gene ir has the highest expression







The formula (2.2.3) can have a Bayesian decision-theoretic interpretation, where a
Bayes optimal rule is chosen among a set of possible decision rules by minimizing the
Bayes risk. However, this Bayesian optimality only applies when the gene set used for
classification has been determined. Otherwise, the Bayes classifier requires the knowledge
of the joint probability distribution of genes and classes, which is a formidable task.
Details of the interpretation and some possible extensions of (2.2.3) are discussed in
Section 2.5.1.
In practice, for further breaking ties among gene sets with the highest score, a sec-
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(−p̂rj) ln p̂rj. (2.2.4)
Here
∑m
r=1 (−p̂rj) ln p̂rj is the entropy of the estimated (class conditional) distribution
for the expression comparison on the j-th row of Table 2.2. The smaller the entropy is,
the more “peaked” the estimated distribution is in a certain class, which can lead to a
more accurate classification rule. As a result, the secondary score (2.2.4) is defined as
the sum of entropies for all possible expression comparisons. Each top scoring set that is
finally chosen is also required to minimize this secondary score.
Decision rule
For each top scoring set S̃, the prediction for sample x is
ŷ = argmax
c=1,2,..m
{xic , ic ∈ S̃}. (2.2.5)
When m = 2, equation (2.2.5) turns out to be (2.2.1). Therefore, TSS is essentially a
generalization of TSP in the multiclass case.
Although it rarely happens, due to expression level ties the decision rule for a single
top scoring set can produce multiple classes associated with genes whose expression is
the highest. In this situation, a randomized decision is introduced where each associated
class is assigned a vote of 1/T, where T is the number of genes producing the tie. For
the final prediction, these votes are summed over the top scoring sets and the majority
rule is applied.
Generally, finding the maximum element are one of the simplest types of analysis that
can be drawn by comparing a set of elements. Because of this simplicity, the relation
tends to be more robust against noise in the data, compared to any complex relations of
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elements. For example, in the TST classifier [57], all possible permutations of a set of
three genes are utilized to search for top scoring triplet(s) in a similar fashion of TSS.
However, in principle, there are six possible permutations of their expression values, and
the sample size needs to be large enough to estimate all class conditional probabilities
associated with each permutation. The frequency estimates of a permutation can have a
large variance if the sample size is small. Therefore, TST is less likely to be robust than
TSS in the small-sample learning situation.
2.2.3 Greedy Search
In theory, TSS finds top scoring sets among all possible gene sets. For a data set
with G genes and m classes, an exhaustive search has the complexity O(Gm), which
grows exponentially with respect to G. Hence, it is quite necessary to relax the global
optimality requirement, which can be done in various ways. One idea would be to a priori
reduce the search space. This can be typically done by pre-selecting a small number of
genes based on a univariate multiclass criterion such as the one-way ANOVA F-test or
the relative non-parametric Kruskal-Wallis test. Also, as presented in the next chapter,
it is possible to use pathway information to restrict the search within naturally defined
groups of genes. In this section, however, a different idea is proposed that adopts a greedy
search algorithm to select gene sets that are top scoring in each of several stages, leading
to what could be called locally optimal scoring sets.
For an m-class problem, the greedy search algorithm takes m−1 steps to form m-gene
sets that are used in the final decision rule. It is initialized by finding the collection of






Next, each possible two-class sub-problem is augmented by a single class, and for every
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such augmentation, a collection of three-gene sets with the highest score is found based
on top scoring gene pairs obtained in that two-class sub-problem. In particular, a distinct
gene is added to each of such gene pairs to yield a group of three-gene sets, among which
the ones with the highest score are sought. Then, the algorithm is performed iteratively
until the size of sub-problems reaches m, and a collection of m-gene sets with the highest
score is obtained from each sub-problem of size m. Finally, the (locally optimal) top
scoring sets are found among all such collections for building a TSS classifier.
The greedy search process is illustrated in Figure 2.3. Since the first step involves two
classes and each subsequent step deals with one more class, the formation of an m-gene
set requires m − 1 steps. Importantly, all possible sequences of classification problems
that start with a two-class problem and augmenting by one class at a time until reaching
m classes are considered, so that ultimately, there are m!/2 collections of m-gene sets to
be compared. The complexity of the first step is O(G2), and each following step only
requires O(G · l) additional computations where l is the maximum size of collections of
gene sets with highest scores generated in the previous step. Because the number such
sets for a certain sub-problem is expected to be small, l is typically small so that the
fully implemented algorithm has O(G2) complexity, which is significantly lower than the
O(Gm) complexity of an exhaustive search for m > 2.
The TSS classifier built by the greedy algorithm is typically validated by cross-
validation. Normally, the greedy algorithm is assumed to be performed in each itera-
tion of the cross-validation loop, which can lead to relatively extensive computation. To
address this difficulty, an acceleration algorithm has also been introduced (see Section
2.4.2) that extends the pruning algorithm introduced by [83] for the TSP classifier to the
multiclass case. In principle, the acceleration algorithm applies the greedy search method
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Figure 2.3: Schematic diagram of the greedy search algorithm. The workflow of the
algorithm is illustrated for a four-class problem. Blue arrows represent the initialization
step where each possible two-class sub-problems are considered. Each red arrow denotes
an augmentation of the current problem by a single class. The graph shows one possible
sequence of augmentations.
only one time on the entire data set and generates a small list of gene sets. Then, the top
scoring sets identified from the list in each iteration of the cross-validation are guaranteed
to be the same as those obtained by applying greedy search on the reduced training set.
The greedy algorithm is not likely to find gene sets having the globally maximum
score. However since it is based on iterating through gene sets with highest scores in
each possible sub-classification problem, the resulting efficiency gain appears substantial
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enough to compensate for the fact that the space in which the search is carried out is
limited, and produces high-scoring gene sets for the original problem. Also, since all
possible sizes of sub-problems are investigated sequentially and only gene sets with the
highest score are kept in each iteration, the final top scoring sets can be globally optimal
if the global solution is also optimal in each of these sub-problems. In particular, this
happens when the top scoring sets obtained by the algorithm have a perfect score.
2.2.4 Error Estimation
Error estimation always plays an crucial role in evaluation of classification methods,
and it is frequently used as the guidance for selecting the best approach. The simplest
metric often considered is misclassification rate (or equivalently classification accuracy).
Its calculation is very efficient and immediately applies to any number of classes. One
of the main drawbacks of misclassification rate is that it only indicates the performance
of a trained classifier at a single operating point, which is controlled by the classification
threshold used. In view of this limitation, a popular criterion preferred is the receiver op-
erator characteristic (ROC) analysis. This analysis constructs an ROC curve by plotting
sensitivity (true positive rate) versus one minus specificity (false positive rate), varying
the decision threshold over its whole range. ROC analysis typically allows a classifier to
be inspected over a range of possible conditions, and produces a scalar as the performance
measure known as “the area under the ROC curve” (AUC). The AUC summarizes model
performance over all possible thresholds, and the evaluation of classifiers based on AUC is
typically independent of class priors, misclassification costs, and operating points. There-
fore, AUC-based metrics have been extensively used in many areas. The original AUC
measure is however only applicable to the two-class case. Hence, there are many attempts
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for extending this popular metric in the multiclass setting. The approach discussed here
is the one proposed by Hand and Till [40]. They suggested a simple extension of using







M denotes the multiclass AUC, and Â(i|j) is the estimated AUC of class i and j, or
more formally, the probability that a randomly drawn member of class j will have a
lower estimated probability of belonging to class i than a randomly drawn member of
class i. This approach simply averages the AUCs resulting from K(K − 1) pairwise class
comparisons (note that Â(i|j) 6= Â(j|i)).
The misclassification rate and the multiclass AUC are both considered for model
evaluation in this thesis. In order to apply them to real data, some sampling strategies are
often needed. There are two commonly used techniques. The first one is the “train-test
split” scheme. The data are partitioned (either naturally or randomly) into a training
and a test set. The training set is used for model optimization and fitting. The test
set is for assessing the performance of the final chosen model. The second method is
the “cross-validation” scheme. The data are partitioned into several roughly equal-sized
folds. These folds are chosen as the test set one at a time, and each time the training
set is selected as the data excluded the test set. A particular form of cross-validation
employed throughout this thesis is leave-one-out cross-validation (LOOCV). If the data
has N samples, LOOCV is a N -step loop. At each step, one distinct sample is left out
while a classifier is trained on the remaining data and is tested the excluded sample. The
final evaluation is based on N prediction results.
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2.2.5 Ensemble Classification
Ensemble classification refers to the strategy of combining decisions of multiple clas-
sification models to reach a final prediction, and is often used for achieving a better clas-
sification performance. Ensemble methods are quite popular in general machine learning
or pattern recognition problems, and they have also been applied to the gene expression
domain [17, 83]. In principle, TSS is analogous to a decision stump (one-level decision
tree), a simple decision rule that is flexible to be combined with any ensemble strategy.
In this section, three main approaches are introduced to ensemble TSS for classification.
The most straightforward approach to ensemble classification when there are several
classifiers is the majority voting. To implement this in the TSS method, instead of
searching for the gene set with the highest score, those corresponding to the top k scores
can be collected for majority voting. The final decision is the class that receives most
votes, and ties, if any, are broken at random. A similar version of this ensemble approach
has been adopted for TSP in the k-TSP method [83]. The only problem remaining
here is the method for choosing k, which can be subjective. Re-sampling procedures for
determing k such as cross-validation or Bootstrapping are often considered.
Majority voting assigns equal weights to all decision rules in the ensemble. An im-
provement might be achieved if more appropriate weights can be computed. In this in-
stance, boosting is a classic example. It was first introduced by Freund and Schapire [29],
with their AdaBoost algorithm for the two-class classification problem, and has been re-
garded as one of the most powerful techniques in supervised learning. An extension of
AdaBoost, known as “SAMME”, to the multiclass case was introduced by Zhu et al. [95].
Table 2.3 provides a brief description of SAMME when combined with TSS. Like the
majority voting scheme, the number of boosting steps M here has to be determined.
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Table 2.3: Description of the “SAMME-TSS” algorithm.
SAMME-TSS
Input: Training set L = {(x1, y1), (x2, y2), ..., (xN , yN )} with m classes.
Output: Decision rule C(x) for a sample x to be classified.
Algorithm: 1. Initialize the weights for samples ωi = 1/N, i = 1, 2, ..., N .
2. For j = 1 to M :
(a) Fit a TSS classifier T
(j)
L to the training data using weights ωi.
(b) Compute err(j) =
∑N
i=1 ωi · I{yi 6=T (j)L (xi)}.




(d) Update N weights as ωi · exp(α(j) · I{yi 6=T (j)L (xi)}).
(e) Re-normalize ωi.








The last ensemble approach discussed here is random forests. Random forests con-
struct a number of decision trees and produces the final prediction through a majority
vote by individual trees. In the well-known algorithm of random forests developed by
Breiman [7], each of individual trees is fully grown but each node split in the tree is based
on a small and random collection of features. If TSS is viewed as one level decision tree,
the same idea can be used to ensemble TSS. To be specific, a multitude of TSS classifiers
are constructed using the training data. Each classifier is built through an exhaustive
search (for the top scoring set) in a few randomly chosen features. The final prediction
is the mode of the classes selected by individual classifiers. The number of randomly
chosen features is often pre-specified and is much less than the actual number of features.
Therefore, this scheme can be very efficient.
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Ensemble methods usually are able to achieve improved performance, but they tend
to decrease the transparency and interpretability of the final decision rule. However, the
failure to provide an interpretation does not necessarily diminish the potential clinical
usefulness of biomarkers with unknown biological functions. Therefore, ensemble classifi-
cation is tested in this chapter for determining potential improvements in the predictive
performance of TSS on real microarray data.
2.3 Code Implementation
The TSS approach has been implemented using R 3.0.0 (http://www.r-project.org/)
and C++. The interface between R and C++ is provided by the R package Rcpp
(http://cran.r-project.org/web/packages/Rcpp/index.html). Besides the classification
approach, methods proposed in this thesis for classifier training such as the greedy search
algorithm have also been implemented in R. In this section, detailed instructions for using
the corresponding R codes (http://jshare.johnshopkins.edu/dnaiman1/public html/tss)
are provided, including the configuration for the R environment, the data format and
parameters for major functions.
The first step is to install the R software and the package Rcpp. The exact instructions
may vary on different operating systems. Here are the steps for installation on Windows
7 Pro x64:
1. Download R (http://cran.r-project.org/bin/windows/base/) and run the installa-
tion.
2. Install Rtools (http://cran.r-project.org/bin/windows/Rtools/) that has the tool
chain required for C++ code compilation.
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3. Download batchfiles (http://cran.r-project.org/contrib/extra/batchfiles/) to always
point to the latest version of R on the system when running R from the command
line.
4. Download the Redmond Path Utility (http://download.cnet.com/Redmond-Path/3000-
2094 4-10811594.html) to alter PATH variables of the system.
5. Edit the PATH variable to allow system wide access to the current version of R on
the computer and components of Rtools.
6. Restart the system. Open R and install Rcpp by running the command:
install.packages(‘‘Rcpp’’).
More details can be found on the website: http://www.r-bloggers.com/installing-rcpp-
on-windows-7-for-r-and-c-integration/. After successfully installing Rcpp, the next step
is to load Rcpp using the library (or require) command in R:
> library(‘‘Rcpp’’)
Once Rcpp is loaded, the primary function for the TSS approach can be acquired by:
> sourceCpp(‘‘TSS.cpp’’)
Here assume all codes at http://jshare.johnshopkins.edu/dnaiman1/public html/tss/R
scripts/ are downloaded and placed in the same folder accessed by R.
Before introducing any specific function, users need to understand how to format
the data. For use of the package, the data is assumed to take the form of a numerical
matrix that contains expression levels from many microarray experiments where values
in each row represent measurements for a particular gene across all patient samples and
values in each column represent expression levels for a certain sample across all genes.
This data format is very typical for functions handling gene expression data, and can
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be created from scratch, loaded from external (e.g. Excel) files or extracted from widely
used ExpressionSet objects in R. For example, to load the sample data set, the following
R commands are used:
> trainData = read.csv(’Leukemia1 train.csv’,header=F,row.names=1)
> testData = read.csv(’Leukemia1 test.csv’,header=F, row.names=1)
> class = c(as.numeric(trainData[1,]),as.numeric(testData[1,]))
> trainData = as.matrix(trainData[-1,])
> testData = as.matrix(testData[-1,])
> dataM = cbind(trainData,testData)
In the codes above, two numerical matrices have been loaded as trainData and
testData, and have been combined into a single matrix dataM. The class labels are
stored in the first row of each matrix. Categorical classes need to be converted into







The sample gene expression data contains microarray measurements for 7129 genes
and 72 samples, which are grouped into 3 classes with 38, 9 and 25 samples respectively.
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> data(Golub Train)
> data(Golub Test)
> trainData = exprs(Golub Train)
> testData = exprs(Golub Test)
> dataM = cbind(trainData,testData)
After obtaining the data matrix and class labels, it is now possible to determine the
TSS classifier. A simple example is as follows:
> geneIdx = c(1:10)
> geneSets = t(combn(geneIdx,3))
> tss = TopScoringSet(dataM,class,3,geneSets)
Here the sample data set contains 3 classes, so the TSS approach aims to find the top
scoring 3-gene sets. geneIdx specifies the indices of genes of dataM used to form the














among which the TopScoringSet function returns the top scoring sets. In general,
TopScoringSet takes a numerical matrix (expression data), a numerical vector (class
labels) and an integer (number of classes) as arguments. Additionally, a numerical matrix
41
CHAPTER 2. TOP SCORING SET
geneSets needs to be provided as the collection of gene sets considered where each row
of the matrix corresponds to the indicies of a single gene set (as shown above).
The output of the TopScoringSet function is a list object that contains a number
of sublists where each sublist includes all information for a single top scoring set. The











The result here indicates that there exists only one top scoring set consisting of the
7-th, 9-th and 10-th gene of dataM. The top score is 1.31 and the classes where each gene
achieves the maximum expression level relative to the other two genes are contained in
class. In addition, the frequency estimate of the “max” gene in each class is included
in classScore.
The top scoring set in the example above has the score of 1.31, which is significantly
42
CHAPTER 2. TOP SCORING SET
lower than the perfect score 3. This is mostly due to the restriction to use only the first 10
genes. In principle, geneSets has to include all possible 3-gene sets that can be formed
from 7129 genes of dataM. However, as discussed in the “Greedy Search” section, this
leads to an exhaustive search that has an undesirable computational complexity. There-
fore, geneSets often needs to be pre-selected, which can be done in various ways. For
example, the Kruskal-Wallis test can be used for this purpose:
> source(’KWTest.r’)
> geneIdx = KWTest(dataM,class,100)


























combinations form geneSets. The result then seems to be significantly
improved by this pre-selection. The top scoring set is a single gene set consisting the
758-th, 2833-th and 3433-th gene of dataM, ane this set achieves a high score of 2.95.
The later two genes have the maximum expression levels in 100% of samples in class 1
and 2 respectively.
The Kruskal-Wallis test works well as an efficient filtering method for the example
here, but as discussed before, it may not perform well in general. One effective approach
proposed in this thesis is the greedy search algorithm, which could address the limitations
of common univariate tests as filtering methods for the TSS classifier. The codes for using
this algorithm are given below:
> classM = t(combn(c(1:3),2))





> setList = GreedySearch augt(dataM,class,3,classM,setList)
The greedy search algorithm contains an initialization step and several augmentation
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steps. The initialization step starts by working on each possible pair of classes, which are
specified in classM. After the initialization step, each pair of classes is augmented by a
new class and the process is repeated until no new class exists. The augmentation process
needs only one function (GreedySearch augt) call that loops over all augmentation
steps. Since the sample data above has 3 classes, there is actually only one augmentation
step carried out by the greedy search algorithm. The resulting setList is a list object
consisting a number of sublists, each of which contains all candidate gene sets (for top
scoring sets) for a particular augmentation path (i.e., sequence of augmentations, see








As shown above, these three sublists consist of 7, 1 and 73 3-gene sets respectively.
In the final step of greedy search, gene sets obtained from all augmentation paths are
collected as candidate gene sets. But duplicates need to be removed because no duplicates
are allowed in the list of top scoring sets. The following codes are implemented for this
purpose:
> geneSets = integer(0)
> for(i in 1:length(setList))
> geneSets = rbind(geneSets,setList[[i]])
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> for(i in 1:dim(geneSets)[1])
> geneSets[i,] = sort(geneSets[i,])
> st = rep(1,dim(geneSets)[1])
> for(i in 2:dim(geneSets)[1])
> for(j in 1:(i-1))
> if(sum(geneSets[i,]==geneSets[j,])==3)
> st[i] = 0
> geneSets = geneSets[st==1,]
> dim(geneSets)
74 3
The ultimate collection contains 74 unique gene sets from greedy search, and a TSS
classifier is built as follows:
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$classScore
1.0000000 0.9736842 1.0000000
The TSS classifier has 73 top scoring sets with the same top score 2.97. Compared
to the result of using the Kruskal-Wallis test, the greedy search algorithm seems to work
better by finding top scoring sets with higher score, which is also done by searching within
fewer candidates. But it is important to be mindful that the greedy search algorithm is
likely to need considerably more computational effort than common univariate tests.
One such top scoring set consisting of the 88-th, 2642-th and 4342-th gene of dataM
is illustrated above. Finally, the classifier tss can be used to predict the classes of
unlabeled samples as follows:
> source(’predict TSS.r’)
> predclass = predict TSS(tss, testData)
The predict TSS function takes the object returned by TopScoringSet and a nu-
merical matrix (test set) as arguments. Note that testData here is assumed to have the
same group of genes with the same indices as in the training set. As a result, predclass
contains class predictions in the same format as for class used in the training process
(sample IDs are shown):
> predclass
V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14 V15 V16 V17 V18 V19 V20 V21
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 3 1 3 1
V22 V23 V24 V25 V26 V27 V28 V29 V30 V31 V32 V33 V34 V35
2 1 1 3 2 3 2 1 3 3 1 2 1 1
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2.4 Validation
2.4.1 Classification of Human Cancer Microarray Data
The TSS classifier was validated on seven gene expression microarray data sets re-
trieved from public databases or authors’ websites (Table 2.4). They are related to
human cancers including leukemia (Leukemia), mixed lineage leukemia (MLL), lung ade-
nocarcinoma (Lung), small round blue cell tumors (SRBCT), bladder carcinoma (Blad-
der), childhood acute lymphoblastic leukemia (ChildALL) and non-small cell lung can-
cer (NSCLC). The types of problems range from classification of cancer subtypes (e.g.,
Leukemia, SRBCT and NSCLC), tumor stages (e.g., Lung and Bladder) and treatment
responses (e.g., ChildALL). Data sets with GEO accession number are obtained from the
Gene Expression Omnibus website (http://www.ncbi.nlm.nih.gov/geo/). Most data sets
were produced using Affymetrix platforms with the exception that SRBCT was generated
using a customized cDNA micoarray. Standard data preprocessing methods were applied.
Some of these data sets have already been investigated previously [60, 83] for evaluating
gene expression classifiers. Additional information can be obtained from the references
included in Table 2.4.
The top scoring gene sets found on seven data sets are summarized in Table 2.5.
For each data set, top scoring sets have been obtained by applying the greedy search
algorithm on all samples. The corresponding top score and re-substitution error have
also been calculated.
In summary, there are 73 top scoring sets for Leukemia, seven sets for MLL, three sets
for Bladder, two sets for SRBCT and NSCLC, and one for Lung and ChildALL. Only
a few genes are actually involved in these sets and most genes appear in multiple sets.
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Table 2.4: Seven gene expression data sets used for evaluating classification performance.
Dataset Platform #Classes #Genes #Samples Source Reference
Leukemia Affymetrix HuGeneFL 3 7129 72 Authors’ website [35]
MLL Affymetrix HGU95 3 12582 72 Authors’ website [3]
Lung Affymetrix HuGeneFL 3 7129 96 Authors’ website [5]
SRBCT cDNA 4 2308 83 Authors’ website [85]
Bladder Affymetrix HuGeneFL 3 7129 40 GEO: GSE89 [21]
ChildALL Affymetrix HGU95 4 12625 60 GEO: GSE412 [9]
NSCLC Affymetrix HGU95 3 12599 33 GEO: GSE1987 [13]
Table 2.5: Top scoring gene sets identified on seven gene expression data sets.
Dataset No. of sets No. of genes Score Error
Leukemia 73 36 2.97/3.00 1/72
MLL 7 12 2.96/3.00 1/72
Lung 1 3 2.72/3.00 16/96
SRBCT 2 5 3.93/4.00 2/83
Bladder 3 5 3.00/3.00 0/40
ChildALL 1 4 3.09/4.00 13/60
NSCLC 2 6 2.88/3.00 1/33
It is interesting to note that some of these genes would not be regarded as differentially
expressed based on their individual expression values, but the relative comparison of ex-
pression levels in each top scoring set produces enhanced class separability. The observed
frequencies of some top scoring sets are displayed in Table 2.6. For each set, the table
gives the relative frequency at which the maximum expression value appears among genes
in the set for every class. In each case, these relative frequencies provide good evidence
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for discriminability of the set, which indicates the potential for class prediction.
Table 2.6: Observed frequencies of gene expression comparison in two top scoring sets
from (a) NSCLC and (b) SRBCT respectively.
(a)
Max gene
Class KRT14 CNGB1 GDF10
SCC 1 0 0
ADCA 0 1 0
N 0 0.12 0.88
(b)
Max gene
Class GYG2 EST CDH2 HCLS1
EWS 0.93 0 0.07 0
RMS 0 1 0 0
NB 0 0 1 0
BL 0 0 0 1
Next, to validate the greedy search-based TSS (G-TSS), its classification accuracy was
assessed on seven microarray data sets. As a comparison to the greedy search algorithm,
a common differential expression technique was considered based on the Mann-Whitney
test and the “1-vs-all” strategy to select top n genes for separating each class from the
union of other classes. To save computation time, n was chosen to be 50 for three-class
and 25 for four-class problems. The resulting TSS classifier (denoted as “MW-TSS”) was
compared to G-TSS in terms of classification accuracy. Furthermore, five popular machine
learning techniques were also considered as benchmarks to the TSS approach: k-nearest
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neighbors (kNN), naive Bayes (NB), random forests (RF), support vector machines with a
linear kernel (l-SVM) and PAM. No feature selection algorithm is applied to benchmark
methods. All analyses were performed using packages in R 3.0.0. LIBSVM [10] was
used as the implementation for SVMs. There are a variety of model choices provided
by LIBSVM and the linear kernel SVM is suggested for microarray data. In particular,
multiclass problems are handled by LIBSVM using the “1-vs-1” approach.
The performance of a classifier was measured by classification accuracy through leave-
one-out cross-validation (LOOCV). For classifiers with parameters (e.g., the number of
nearest neighbors k in kNN and the cost factor C in l-SVM), the performance evaluation
was realized by a double LOOCV loop. To be precise, a double LOOCV loop consists of
an inner loop and an outer loop, both of which use the leave-one-out partition scheme.
For each classifier model, the inner loop is responsible for model optimization that usu-
ally involves parameter tuning, and the outer loop is used for calculating accuracy by
averaging classification results. To avoid any optimistic evaluation result, each step of
the outer loop is accomplished so that the training data on which the model optimization
is performed is totally independent of the left out testing sample.
Table 2.7 provides a comparison of classification accuracies for different methods on
seven data sets. In general, G-TSS has achieved comparable or better performance on
most data sets. For Leukemia and MLL, it competes with the highest accuracies ob-
tained by PAM and NB respectively. For Bladder, ChildALL and NSCLC, it turns out
to be the most accurate classifier. In contrast, MW-TSS only yields comparable results on
Leukemia and NSCLC and has the lowest accuracies on four out of seven data sets, which
seems to indicate the inappropriateness of using traditional differential expression meth-
ods that focus on individual expression values to search for relative expression patterns.
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Table 2.7: Comparison of classification accuracies estimated using LOOCV. The highest
accuracy for each data set is highlighted in boldface.
Method Leukemia MLL Lung SRBCT Bladder ChildALL NSCLC
G-TSS 95.83 94.44 70.83 90.36 100.00 48.33 90.91
MW-TSS 95.83 76.39 62.50 89.15 57.50 36.67 87.87
kNN 81.94 91.67 75.00 95.18 77.50 45.00 72.72
NB 94.44 95.83 75.00 98.80 82.50 46.67 66.67
RF 93.06 94.44 78.13 100.00 90.00 48.33 72.72
PAM 97.22 93.06 70.83 100.00 85.00 31.67 69.70
l-SVM 93.06 94.44 83.33 100.00 92.50 41.67 81.82
These results demonstrate the superiority of the greedy search algorithm for building the
TSS classifier.
In this study, kNN, NB, RF and l-SVMmake use of all available genes for classification.
Although their performances could often be improved by feature selection or ensemble
approaches, investigation of such improvements is beyond the scope of this thesis as
the goal is not to merely develop a more accurate classifier. Instead, the competitive
performance of TSS across all data sets demonstrates its stability. More importantly, the
TSS approach is able to discover small informative subsets of genes, and its decision rule,
compared with those of benchmark classifiers, proves to be much simpler, hence is more
likely to provide for improved biological interpretability without a concomitant sacrifice
in performance.
A Large Sample Case
While the predictive ability of the TSS classifier has been demonstrated across seven
gene expression data sets, these data sets generally have a very limited sample size and
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a small number of classes. To address these limitations, an attempt was made to apply
the TSS approach to one extreme case: the Microarray Innovations in Leukemia (MILE)
study program [37]. MILE is claimed as one of the largest gene expression microarray
profiling studies in hematology and oncology. The expression profiles are collected from
11 laboratories in seven countries across three continents and consist of leukemia subtypes
of myeloid and lymphoid malignancies. MILE is a two-stage study where a retrospective
stage I generated expression profiles for 2,143 patients and was designed for biomarker
discovery. A prospective stage II produced an independent cohort of 1,152 patients and
was used for validation. Stage I used commercially available whole-genome microarrays
(Affymetrix HG-U133 Plus 2.0) and stage II was performed using a newly designed custom
chip (Roche AmpliChip). The microarray data have been deposited in Gene Expression
Omnibus database under series accession number GSE13204.
MILE provides an unique opportunity for validating microarray-based classification
models, especially for multiclass approaches. Each of 2,143 samples in stage I contains
54,675 gene expression measurements (45 missing values). Samples are classified into 18
diagnostic gold standard categories including eight ALL subtypes, six AML subtypes, two
chronic leukemia subtypes, myelodysplastic syndromes and normal bone marrow. Stage II
contains only 1,480 (1,457 disease-related and 23 housekeeping) genes and samples are also
classified into 18 classes as defined in stage I. In the initial MILE study, a classification
model was trained and tested for distinguishing all 18 classes. The multiclass model
consists of binary classifiers formed by support vector machines with a linear kernel (l-
SVM), each of which separates a pair of classes. In the results, high accuracies were
observed for most classes, indicating the robustness of microarray-based classification.
To compare the predictive performance, a classification model was trained using the TSS
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approach on stage I samples and tested independently on samples from stage II. Since in
the original MILE paper, the independent validation results were only shown for an acute
leukemia diagnostic classifier, all 14 acute leukemia subtypes (Table 2.8) are considered
here. Also, both training and test set contain only 1,457 genes that are in common for
microarray data sets from two stages.
Although in thoery the TSS approach can be applied to any number of classes, the
predictive power of top scoring sets through relative comparison is expected to decrease
as the number of classes under study increases. Also, since the class hierarchy of acute
leukemia subtypes is known a priori, it is better to incorporate such biological information
to guide the decision process. Therefore, for this large multiclass problem, a two-step
decision tree as shown in Figure 2.4 was introduced based on three TSS classifiers. The
hierarchy of the tree is generated from the structure of the data where 14 acute leukemia
subtypes can be grouped into three major lineage leukemias (B-ALL, T-ALL and AML).
The B-ALL class is further divided into seven subtypes while the AML class contains six
subtypes. As a result, three TSS classifiers were built for a three-class, six-class and seven-
class problem respectively. The final prediction for a sample would follow the decision
tree. In addition, to further improve the predictive performance, a similar procedure as
introduced by [83] was considered to construct an ensemble of TSS classifiers for each
of three multiclass problems. Specifically, the top k scoring gene sets were selected at
each step of the greedy search process and the final prediction was the class receiving
the majority of votes from k chosen gene sets. k was considered as the model parameter
and the best k ∈ {1, 2, ..., 50} was determined by LOOCV on the training set. Also,
the acceleration algorithm was used to expedite the cross-validation process (see Section
2.4.2).
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Table 2.8: Samples of acute leukemia subtypes used for classification. Three major
leukemia classes consist of 14 subtypes. The class labels (C1 to C14) are the same as
defined in the MILE study.
Class Diagnosis No. of samples
Training Test
- B-ALL 576 357
C1 Mature B-ALL with t(8;14) 13 5
C2 Pro-B-ALL with t(11q23)/MLL 70 23
C3 c-ALL/Pre-B-ALL with t(9;22) 122 62
C5 ALL with t(12;21) 58 64
C6 ALL with t(1;19) 36 10
C7 ALL with hyperdiploid karyotype 40 35
C8 c-ALL/Pre-B-ALL without t(9;22) 237 158
C4 T-ALL 174 79
- AML 542 257
C9 AML with t(8;21) 40 16
C10 AML with t(15;17) 37 20
C11 AML with inv(16)/t(16;16) 28 20
C12 AML with t(11q23)/MLL 38 17
C13 AML with normal kt./other abn. 351 160
C14 AML complex aberrant karyotype 48 24
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Acute Leukemias
B-ALL T-ALL AML
C1 C3C2 C5 C6 C7 C8 C9
C4
C10 C11 C12 C13 C14
Figure 2.4: Two-step decision tree for classification of acute leukemia samples.
Prediction accuracies of G-TSS are shown in Table 2.9 and are compared to those
achieved by l-SVM as presented in [37]. The optimal k for the ensemble of TSS classifiers
in the three-, six- and seven-class problem (Figure 2.4) is 12, 7 and 42 respectively. G-TSS
has achieved 100% correct predictions for two classes (C1 and C6), and > 90% accuracies
for three classes (C4, C5 and C10). It outperforms l-SVM in three classes, and yields
equal results in four classes. In general, there are at least 10 out of 14 classes in which
comparable accuracies have been obeserved for both methods. For G-TSS, low accuracies
are observed for C8, C12 and C13. For C12, its intrinsically heterogeneous nature has
been discussed in [37]. For C8 and C13, this could be due to the imbalanced training
sample sizes that may violate the equal prior probabilities for classes assumed by TSS.






= 91 SVM classifiers in the MILE study. Many fewer genes are hence
involved in making predictions through G-TSS.
For a more comprehensive comparison, the two-step decision tree was also considered
to combine with l-SVM (denote this approach as Hierarchical SVM or HC-SVM) where
three l-SVM classifiers were trained for three multiclass problems. In each problem,
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HC-SVM still used the one-vs-one scheme to handle multiple classes and the parameter
tuning was realized using 10-fold cross-validation on the training set. Table 2.9 shows
that HC-SVM has achieved similar accuracies to G-TSS and l-SVM in most classes. For
C3, C5 and C14, the accuracy of HC-SVM is significantly lower than that of G-TSS
and l-SVM, but good results have been observed in C8 and C13. Overall, the comparison
demonstrates the effectiveness of G-TSS on a large data set. Its classification performance
is as powerful as that of advanced machine learning classifiers while its decision boundaries
remain transparent and potentially interpretable.
2.4.2 Cross-Study Comparison of Bladder Cancer
Bladder cancer is a common malignant disease that causes 145,000 deaths worldwide
annually [22]. According to American Cancer Society (www.cancer.org/), the stage of
disease at diagnosis is one of the most important factors in choosing treatment options
and predicting a person’s prognosis. A staging system is a standard way to describe
the extent of cancer spread. For bladder cancer, a common staging system used is the
“T” system where the letter T is followed by numbers and/or letters to describe how far
the primary tumor has grown through the bladder wall and whether it has grown into
nearby tissues. Higher T numbers mean more extensive growth. Bladder cancer typi-
cally progresses from stage Ta (non-invasive papillary carcinoma) or Tis (non-invasive flat
carcinoma) to T1 (grown into the connective tissue below), T2 (grown into the muscle
layer), T3 (grown into the fatty tissue layer) and T4 (spread into nearby organs or struc-
tures). Non-muscle-invasive tumors (Ta and T1) and muscle-invasive tumors (T2-T4)
differ significantly in clinical treatment. Hence, there are many attempts for identifying
prognostic variables of bladder cancer stages, and gene expression-based approaches have
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Table 2.9: Comparison of acute leukemia classification methods. The number of correct
classifications is followed by the corresponding accuracy (in percentage) for each class.
Class G-TSS l-SVM HC-SVM
C1 5 (100.0) 4 (80.0) 4 (80.0)
C2 20 (87.0) 23 (100.0) 21 (91.3)
C3 51 (82.3) 53 (85.5) 34 (54.8)
C4 75 (94.9) 75 (94.9) 74 (93.7)
C5 62 (96.9) 59 (92.2) 13 (20.3)
C6 10 (100.0) 10 (100.0) 10 (100.0)
C7 30 (85.7) 22 (62.9) 32 (91.4)
C8 76 (48.1) 141 (89.2) 138 (87.3)
C9 14 (87.5) 16 (100.0) 16 (100.0)
C10 19 (95.0) 19 (95.0) 18 (90.0)
C11 17 (85.0) 20 (100.0) 16 (80.0)
C12 11 (64.7) 15 (88.2) 15 (88.2)
C13 127 (79.4) 148 (92.5) 156 (97.5)
C14 17 (70.8) 17 (70.8) 9 (37.5)
also been investigated. Dyrskjot et al. [22] conducted one of the largest cohort studies
of bladder cancer. Microarray profiles of 404 patient samples diagnosed with bladder
cancer were collected in hospitals in Denmark, Sweden, France, England, and Spain. A
variety of classification tasks were performed using gene expression with respect to stage,
recurrence, carcinoma in situ and progression to validate the prognostic value of molec-
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ular classifiers. In this section, the classification of cancer stages is focused using the
same microarray data, and the TSS classifier is considered to combine several ensemble
methods.
Leave-Study-Out Cross-Validation
The bladder cancer data in [22] consists of patient samples collected independently
from five locations. Since the batch/study effects of microarray data are widely observed
[54], microarray classifiers are expected to generalize well on an independent test set.
For this purpose, data sets from different platforms or locations are often integrated to
demonstrate the robustness of a certain classifier. Specifically, in this section, classifiers
are validated using a procedure called leave-study-out cross-validation. Each iteration
of this procedure reserves samples from one location for testing and uses all other ones
for training. The results from all iterations are then aggregated to estimate classification
performance.
Table 2.10 summarizes the information of bladder cancer patients. The microar-
ray data is publicly available using GEO (Gene Expression Omnibus) accession number
GSE5479. Gene expression profiling was assayed on custom cDNA microarray. Prepro-
cessing methods applied include the Lowess normalization [71] and a log 2 ratio trans-
formation. The final data contains measurements of 1381 genes. Patient samples are
from stage Ta, Tis, T1, T2, T3 and T4, but 10 samples from stage Tis, T3 and T4 are
excluded in this study because of the small sample size. Therefore, the stage classification
considered here is a three-class problem.
Classification performance was evaluated using the multiclass ROC analysis intro-
duced in the “Error Estimation” section. The AUC of a classifier was obtained using
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Table 2.10: Clinical information of bladder cancer patients.
Spain France Denmark Sweden England Total
Stage
Ta 34 25 86 26 17 188
T1 7 19 63 75 8 162
T2 14 17 4 9 – 44
the train-test split strategy where leave-study-out cross-validation was used to partition
the data. Patient samples from England were only considered for training because they
have no samples for stage T2. The G-TSS (greedy search-based TSS) approach was ap-
plied and its AUC was compared with that of four benchmark classifiers including naive
Bayes (NB), random forest (RF), PAM and support vector machine with a linear kernel
(l-SVM). Parameters were tuned using 10-fold cross-validation on the training set.
Table 2.11: Comparison of AUCs across five locations.
Spain France Denmark Sweden Average
NB 64.35 82.93 81.79 68.55 74.41
RF 71.35 80.98 86.40 68.58 76.83
PAM 71.22 76.50 86.96 74.31 77.25
l-SVM 72.95 78.58 83.54 62.54 74.40
G-TSS 70.27 74.4 70.41 58.23 68.33
Results in Table 2.11 demonstrate that AUCs of G-TSS across five locations are
consistently lower than those of any benchmark method, although it is not the worst
classifier in terms of misclassification rates (not shown). This is partially due to the
fact that the calculation of AUC is based on estimates of posterior probabilities used by
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decision rules. The rules of benchmark classifiers typically assign non-zero probabilities
to all classes with the highest probability to the most desirable class, which can benefit
from wrong decisions since there is still a non-zero probability of choosing the “true”
class. In contrast, the rule of TSS is often based on a single top scoring set, and the
possible decision for a class then can only be “yes” or “no”. At a particular decision
threshold (e.g., misclassification rate), TSS seems to achieve better rates, but it can be
less robust in a broad sense.
TSS Ensembles
Motivated by the limitation discussed above, an attempt was made to combine TSS
with ensemble methods described in the “Ensemble Classification” section. In particular,
top scoring gene sets were utilized as “weak” classifiers (classifiers that might not perform
much better than random guessing) and were combined by some voting scheme into a
“powerful” classifier. Specifically, three ensemble schemes were considered and compared:
“k-TSS” collects top k scoring sets obtained by the greedy search algorithm and allows
them to make a majority vote for the final decision; “RF-TSS” imitates the process of
random forest to build a number of TSS classifiers, each of which is based on a small group
of randomly selected genes. Again the majority rule is used to reach the final prediction;
“SAMME-TSS” adopts the “SAMME” algorithm, a multiclass ensemble strategy [95] that
extends the well-known Adaboost method in the multiclass case. Basically, SAMME-TSS
combines gene sets with top scores for prediction with appropriately chosen weights, which
are obtained sequentially by minimizing some pre-defined cost function. Three ensemble
methods were used to improve the classification results.
AUC values at various ensemble sizes for k-TSS are shown in Table 2.12. AUCs were
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calculated for four locations (Spain, France, Denmark and Sweden) whose samples were
tested. These results show that significant improvements in terms of AUC have been
obtained by k-TSS.
Table 2.12: AUCs of k-TSS at various ensemble sizes across different locations.
Ensemble Size Spain France Denmark England Average
No ensemble 70.27 74.4 70.41 58.23 70.27
10 72.62 80.33 80.62 67.88 75.36
50 73.47 80.59 83.08 68.45 76.40
100 73.42 84.41 83.98 69.34 77.79
Also, the AUC values of RF-TSS were achieved in Table 2.13. To be precise, each of
many TSS classifiers in RF-TSS was built through an exhaustive search among a number
of randomly chosen genes. Similar to the random forest setting, the number was selected
as
√
1381 ≈ 37 (square root of the number of genes), and various ensemble sizes were
used for training.
Table 2.13: AUCs of RF-TSS for different ensemble sizes.
Ensemble Size Spain France Denmark England Average
No ensemble 70.27 74.4 70.41 58.23 70.27
10 63.86 67.84 68.12 46.26 61.52
50 65.55 76.63 73.97 56.63 68.20
100 63.45 81.74 75.28 57.35 69.46
AUCs in Table 2.13 show little improvement after using RF-TSS. Some were even
worse for small ensemble sizes. Different random selections were tried and the results
seemed to be similar. The performance of RF-TSS is likely to be degraded by “noisy”
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TSS classifiers in the ensemble. In contrast, k-TSS obtains better results with many fewer
gene sets.
The last method investigated is SAMME-TSS. The algorithm is unambiguously de-
tailed in Table 2.3 except for step 2(a) in which a TSS classifier is built on the weighted
training data. Typically this step is realized by searching for a weak classifier that min-
imizes the weighted error rate. In SAMME-TSS, the set of all weak classifiers was the
collection of top k scoring sets generated by the greedy search algorithm and the mini-
mization was acutally carried out over k elements. The value of k was chosen to be large
enough (k = 10, 000) so that there were enough weak classifiers to choose from.
Table 2.14: AUCs of SAMME-TSS for different ensemble sizes.
Ensemble Size Spain France Denmark England Average
No ensemble 70.27 74.4 70.41 58.23 70.27
10 71.11 86.21 72.85 53.65 70.96
50 64.71 84.53 78.32 56.18 70.94
100 66.6 84.63 78.92 56.3 71.61
The AUCs of using SAMME-TSS were listed in Table 2.14. The results seem slightly
better than RF-TSS, but are generally worse than k-TSS. The performance on some data
(e.g. France) appears to be boosted, and the AUCs typically decrease when ensemble
size increases. The boosting procedure could be limited by the set of pre-selected gene
sets. Overall, k-TSS turns out to be the best ensemble approach for this bladder cancer
cohort study.
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2.5 Theoretical Results
2.5.1 Bayesian Decision-theoretic Interpretation
In section 2.2.2, the formula (2.2.3) was used to calculate the score of a gene set in
the TSS classifier. This section gives a theoretical derivation of this formula and its form
with a general loss function and class priors using the Bayesian decision theory.
For an m-class classification problem, each m-gene set S = {i1, i2, ..., im} selected by
TSS is supposed to satisfy (2.2.2). Now assume the class conditional probability distri-
butions associated with gene expression comparisons in S are given exactly in Table 2.15.
Table 2.15: Class conditional probabilities of expression comparisons associated with S.
Class
y = 1 y = 2 ... y = m
Xi1 > max{Xr, r ∈ S \ i1} p11 p12 ... p1m
Xi2 > max{Xr, r ∈ S \ i2} p21 p22 ... p2m
...... ......
Xim > max{Xr, r ∈ S \ im} pm1 pm2 ... pmm
Then a decision procedure δ for class prediction can be constructed where each com-
parison above is considered being indicative of a sample from a distinct class. Conse-
quently, m comparisons lead to m! possible δs for a given gene set, and one of them is
illustrated below.
Next, a loss function can be introduced for δ by specifying the penalties for each type
of misclassification as in Table 2.17 Based on the tables above, R(i, δ), the risk function
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Table 2.16: Decision procedure δ based on m possible relations resulted from expression
comparison of genes in S.
X δ(X)
Xi1 > max{Xr, r ∈ S \ i1} 3
Xi2 > max{Xr, r ∈ S \ i2} 1
...... ......
Xim > max{Xr, r ∈ S \ im} 2
Table 2.17: Loss function for decision procedure δ
δ = 1 δ = 2 ... δ = m
y = 1 l11 l12 ... l1m
y = 2 l21 l22 ... l2m
... ......
y = m lm1 lm2 ... lmm





lij · p(δ = j|y = i) (2.5.1)
where p(δ = j|y = i) corresponds to one of probabilities in Table 2.15 and can be





πi · R(i, δ) (2.5.2)
where πi is the prior probability for class y = i. According to the Bayesian decision




is the Bayes rule and the corresponding r(δ∗) is the Bayes risk.
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It is important to note that the Bayesian optimality of the decision rule described
above only applies when the gene set used for classification has been determined. Oth-
erwise, the development of the Bayes rule requires the joint probability distribution of
genes and classes. In fact, no theory is directly related to the choice of gene set for
classification. Also, for a chosen gene set, the true probabilities pij and πi are unknown
in nearly any real problem. Although the Bayes rule based on empirical estimates (e.g.,
sample frequencies) of these probabilities is no longer guaranteed to be optimal, it has
been widely considered in practice. Therefore, (2.5.1) and (2.5.2) can be used to find the
prediction risk associated with δ if pij and πi are estimated using sample frequencies p̂ij
and π̂i. As a result, different δs that correspond to the same gene set S can be compared
to achieve the best decision, and the minimum risk resulted can be used as the score of
S. Moreover, the scores of different gene sets can be compared and searching among all
possible gene sets can yield the sets with the globally minimum score – that is the basic
idea of TSS.
In most problems discussed in this thesis, there is no indication of the type of loss
functions and prior distributions, so the 0-1 loss function and the equal class priors are











0 if i = j,
1 otherwise.





lij · p(δ = j|y = i) =
∑
j 6=i
p(δ = j|y = i) = 1− p(δ = i|y = i),
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p(δ = i|y = i).






p(δ = i|y = i) (2.5.4)
As explained before, in most cases, only empirical solution is available for (2.5.4).
Under this circumstance, the formula (2.2.3) is used to heuristically find the best decision
for a given gene set. Then, all possible gene sets are sought for the globally optimal
decision, which turns out to be the top scoring sets.
In addition, different loss functions or class priors can also be considered given the
equation (2.5.2). For example, the empirical class prior πi can be equal to ni/N , where ni
is the sample size of class i and N is the total sample size, but this specification requires
a good knowledge of the class distribution.
2.5.2 The Acceleration Algorithm
The acceleration algorithm described here generalizes the pruning algorithm intro-
duced by [83] for the TSP classifier to the multiclass case. Similar to the binary TSP
method, an important step for the multiclass TSS approach is to search for top scoring
gene sets. Once the search process is completed, the decision rule can be immediately de-
rived. However, given the large number of genes for microarray data, the search process
is often computationally expensive. The greedy search algorithm has been introduced
previsouly for searching gene sets with high scores. It is significantly more efficient than
the exhaustive search, but may not be fast when combined with schemes such as cross-
validation. Therefore, the acceleration algorithm here aims to expedite the search process
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in the cross-validation loop.
When the greedy search algorithm is employed in the search process, only top scoring
sets are kept in the final step. Therefore, gene sets that can not possibly achieve the
top score can be excluded in the search process, which typically requires a “complete”
comparison among all possible gene sets. In a cross-validation loop, one such comparison
is needed for each iteration. However, the acceleration algorithm can produce a small
list of gene sets so that only a comparison among these gene sets is sufficient to find top
scoring sets. Let rg(n) denote the score obtained for a given gene set g when a subset of
n samples is left out from N training samples in the cross-validation. The lower bound
Lg(n) and the upper bound Ug(n) are defined as
Lg(n) ≤ min{rg(n) : any size n subset}
Ug(n) ≥ max{rg(n) : any size n subset}.
Now suppose the lower and upper bounds are obtained for all possible gene sets
{gi, i = 1, 2, ...}. Rank all lower bounds from largest to smallest and set the largest lower
bound to L. Without loss of generality, assume L = Lg1(n). Then the following claim
holds:
Claim: If Ugi(n) < L then the gene set gi can not be a top scoring set on N − n
samples for any size n subset.
Proof: According to the definition of Ugi(n), rgi(n) ≤ Ugi(n). If rg(n) ≤ Ugi(n) < L,
the following inequalities satisfy for any size n subset
rgi(n) ≤ Ugi(n) < L ≤ rg1(n).
Therefore, there is at least one gene set g1 scored higher than gi regardless of the
choice of the size n subset. This claim follows immediately.
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Table 2.18: Description of the acceleration algorithm.
Acceleration Algorithm
Input: N training samples, gene set collection G = {g1, g2, ...}
Output: The reduced gene set list Ω.
1. For each gene set gi, compute the lower bound Lgi(n) and
the upper bound Ugi(n) under all possible situations that n
training samples are left out.
2. Rank all Lgi(n) in descending order and take L =
max{Lgi(n)}
3. Generate the list Ω consisting of all gi for which Ugi(n) ≥ L
The reduced list Ω typically contains only a few gene sets. The identification of top
scoring sets from Ω is extremely fast. The significant improvement in efficiency is hence
achieved by repeatedly using Ω in each iteration of the cross-validation. The lower and
upper bound for a given gene set can be obtained by calculating all possible scores when
any size n subset is left out. Unless a large n and a large number of classes are considered
simultaneously, this process is also efficient.
In practice, G in Table 2.18 can be any gene set collection considered in the search pro-
cess. For example, in the greedy search process, there are a number of sub-classification
problems generated from the original problem. In each of these sub-problems, only top
scoring sets are stored. Therefore, the acceleration algorithm can be applied in each step
of the greedy search to yield a reduced list of gene sets that can possibly be identified as
top scoring sets in the cross-validation. As a result, the greedy search process only needs
to be applied one time on the training set.
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The acceleration algorithm here can be immediately extended for the k-TSS classifier
that uses top k scoring sets as the decision rule. In this situation, only step 2 in Table 2.18
needs to be changed so that L is set to the k-th largest lower bound. This is because any
gene set whose upper bound is less than L clearly can not be one of the top k scoring
sets during the cross-validation. As a result, the search process for top k scoring sets can





High-throughput microarray data pose challenges for most types of statistical analy-
sis. For example, traditional hypothesis tests such as the t-test and the ANOVA F -test
for selecting differentially expressed genes need to be carefully corrected for the multiple
testing problem. Importantly, any statistical learning model proposed on the data has
a high risk of over-fitting due to the “small n, large p” situation. Therefore, dimension
reduction seems to become a necessity in microarray analysis. In early studies, univariate
hypothesis tests were thought to effectively reduce the lists of genes, but different statisti-
cal procedures often produced non-identical lists, many of which had little or no overlap.
As a result, there have always been concerns and discussions about the appropriateness
of these procedures.
As it is well recognized that many functional related genes are typically involved in the
mechanism of complex diseases such as cancers, one popular approach of gene expression
analysis is to investigate these naturally defined sets of genes rather than all the genes
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at once. Pathway-based classification using expression profiles has been shown in recent
studies [32, 50] to provide results that are more biologically meaningful. In particular,
these pre-defined groups of genes provide a natural and efficient dimension reduction.
This chapter demonstrates the ability of the Top Scoring Set (TSS) approach introduced
in Chapter 2 to integrate biological information from traditional pathway analysis for
microarray-based classification.
Pathway Databases
There are three main sources of pathway and functional information, which can be
either generic or species-specific. These might describe metabolic and cellular processes,
and genetic networks. The Gene Ontology project (GO) [41] has developed three struc-
tured controlled vocabularies (ontologies) that describe gene products in terms of their
associated biological processes, cellular components and molecular functions. These three
groups consist of genes with similar functions where genes inside each group are correlated
in a hierarchical structure. The Kyoto Encyclopedia of Genes and Genomes (KEGG) [45]
is a series of databases developed by both the Bioinformatics Center of Kyoto University
and the Human Genome Center of the University of Tokyo. The “Pathway” section of
KEGG provides a plethora of searchable pathways for a diversity of organisms with the
focus on metabolic pathways. GenMAPP [20] provides an image of a pathway that is
annotated with accession numbers. Many gene ontology classifications are also available
from GenMAPP. In addition to the databases introduced here, there are many other
frequently used pathway databases such as BioCarta (www.biocarta.com) and Molecular
Interaction Map (discover.nci.nih.gov/mim/index.jsp).
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Enrichment Analysis
Enrichment analysis refers to the process of identifying groups of genes (rather than
individual genes) that are significantly related to the disease states under study in terms
of expression levels. Gene groups are typically pre-defined to share common biological
function, chromosomal location, or regulation. A common case is to consider pathway
information through various kinds of functional annotations of genes. Compared to the
conventional identification of differentially expressed genes, pathway-level analysis is more
robust to inaccuracies of specific gene expression estimates and provides a more expansive
view of the underlying processes.
There are a number of statistical methods proposed for identifying pathways or func-
tional annotations that are significantly associated with phenotypes under study based
on expression values. In the most common approach, genes are first ordered according
to their evidence for differential expression, by one of many univariate statistical tests.
Then they are examined against each of the gene sets defined by pathways, to determine
whether any set is over-represented (i.e., contains more top genes than other sets) among
the whole list of genes. To examine the evidence of association in this case, Fisher’s exact
test based on the hypergeometric distribution or its large-sample approximation χ2 test
is a routine. However, as mentioned in [84], there are at least three shortcomings for this
approach, and a better solution for enrichment analysis is in need.
A more successfully and widely recognized method is Gene Set Enrichment Analysis
(GSEA) proposed by Subramanian et al. [82]. The method was originally designed for
two-class problems. It works in following steps for a collection of gene sets S1, S2, .., Sn:
1. Compute the t-statistic (z-score) zj (comparing across the two classes) for each gene
j of all N genes in the data.
73
CHAPTER 3. PATHWAY-BASED CLASSIFICATION
2. Generate a summary statistic for each gene set Sk. In GSEA, this statistic is defined
as the enrichment score that is essentially a signed version of the Kolmogorov-
Smirnov statistic between the values {zj , j ∈ Sk} and their complement {zj, j 6∈ Sk}.
The sign is positive if j ∈ Sk and negative if j 6∈ Sk.
3. Permute the sample labels and recompute the statistic on each the permuted
dataset, which generates a null distribution of the enrichment score.
4. Assess the statistical significance (P value, false discovery rate, etc.) of the observed
score and significant gene sets are chosen.
GSEA provides a statistical framework for comparing different pathways, and it has
been extended in many subsequent studies. For instance, Zahn et al. [93] considered a
Van der Waerden statistic in place of the Kolmogorov-Smirnov statistic, and bootstrap
sampling of the arrays instead of a permutation distribution. Significance Analysis of
Function and Expression (SAFE) proposed by Barry et al. [4] extends GSEA to cover
multiclass, continuous and survival phenotypes, and gives two more options for the test
statistic: the Wilcoxon rank sum and the hypergeometric statistic that uses the Fisher’s
exact or its large-sample approximation χ2 test as mentioned above. Efron and Tib-
shirani [25] introduced the Gene Set Analysis (GSA) method that uses a new statistic
called “maxmean”, and developed a restandardization step for producing more accurate
enrichment scores.
Microarray Classification
The successful identification of differentially regulated pathways associated with phe-
notypes of interest through enrichment analysis advances the development of molecular
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classification of diseases. Numerous studies have relied on analysis of individual genes
to find microarray-based molecular markers for discrimination of disease states (e.g.,
subtypes and therapy responses) in experimental and clinical settings. However, such
procedures in complex diseases are often limited by factors such as cellular heterogeneity
within a tissue sample and genetic heterogeneity across patients. As a result, the effective-
ness and reproducibility of many early results have been challenged in follow-up studies.
Moreover, lack of coherence in biological interpretation of these results also prevent them
from being translated into clinical applications. In view of these limitations, a growing
trend is to integrate pathway information into the biomarker identification process, per-
mitting disease classification based on the activity of pathways rather than simply on the
expression levels of individual genes. This section gives a short introduction to some of
the approaches developed for this purpose.
First of all, based on the enrichment methods described in the last section that lead to
detection of statistically significant pathways, genes in those pathways can be considered
for a careful investigation for their association with the disease under study. There is much
evidence in recent studies of correct identification of mechanism-related genes based on
pathway analysis [26, 52]. Second, compared to traditional biomarkers, pathway-based
gene signatures tend to have a high level of concordance, i.e., consistency in terms of
the gene members contained or agreement of analysis results using these signatures. For
example, Fan et al. [28] examined the predictions derived from a number of prognostic
gene signatures for individual samples related to breast cancer, and found that most
models had high rates of concordance in their outcome predictions. As a matter of fact,
nearly all these gene signatures have incorporated some of the main signaling pathways
of breast cancer. Therefore, pathway analysis can play an important role in disease
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classification. In particular, diagnostic and prognostic gene signatures can be sought
directly from statistically significant or mechanism-related pathways for groups of genes
collectively exhibiting consistent expression patterns that allow for distinction among
phenotypes.
In addition to producing gene signatures directly, pathways are more involved in a
variety of statistical learning models developed for disease classification. In this situa-
tion, each pathway is often treated as a functional module where a summary measure is
computed to capture the overall activity level of the module. To be precise, for a certain
patient sample, each module (pathway) activity level is a scalar generated by applying
some mathematical transformation of the raw expression values of genes contained in
that module. As a result, the original high-throughput data is transformed into low di-
mension functional expression profiles, on which many conventional classification models
are built. For instance, Guo et al. [36] considered decision trees on functional expression
data where module activities were computed by simply taking the mean or median of
expression values of module genes. Lee et al. [52] proposed a logistic regression model in
which each activity level was inferred as an averaged z-score derived from the expression
of its individual key genes that generated most discriminative activities between two phe-
notypes. A pathway activity matrix was constructed based on activity levels to train a
classifier. Also, Su et al. [81] inferred a particular pathway activity by first computing the
log-likelihood ratio between different disease phenotypes based on the expression level of
each gene, and combining the log-likelihood ratios of the genes contained in that path-
way. Then, they considered a regular logistic regression or a linear discriminant analysis
model for disease classification. In a recent study by Kim et al. [50], the support vector
machine (SVM) technique was used on 2-level hierarchical data with a basic level of gene
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expression values and an advanced level of pathway activities. In this case, each pathway
activity level was a linear combination of expression values of its member genes and the
weights used were generated by applying a SVM with the whole set of genes.
In summary, pathway-based classification can be performed in two major ways. Within
disease-related or statistically significant pathways, small sets of key genes can be iden-
tified in association with different phenotypes. The expression patterns of these genes
can lead to accurate and biologically meaningful disease classification. At the same time,
numerical patterns of a certain pathway can be inferred and summarized into an acti-
vation level using the expression values of the constituent genes, which generates a low
dimensional dataset with features being the pathway activities instead of gene expres-
sion values. As a result, conventional statistical learning methods become immediately
applicable. In this chapter, the Top Scoring Set method introduced in Chapter 2 is consid-
ered to integrate biological information from pathway analysis, and a new pathway-based
classification approach is proposed later.
Unsupervised Learning
While this thesis is primarily focused on supervised learning problems, part of this
chapter is dedicated to unsupervised learning tasks. For studying gene expression mi-
croarrays, unsupervised techniques are constantly used for identifying unexpected but
biologically interesting patterns in the data. In particular, they are of great importance
to identify clusters in samples when no prior classification of samples is available. In this
chapter, a rank-based unsupervised approach is introduced that is based on hierarchical
cluster analysis, and aims to address the robustness of current clustering techniques as ap-
plied to gene expression microarrays. The method uses the Kendall’s rank coefficient [48]
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as the distance metric, which is consistent with the rank-based transformation used in
other methods in this thesis, and provides a complementary tool to the family of relative
expression analysis methods especially when no prior classes of samples are available or
reliable. In addition, the method is suitable to combine with rank-based classification
methods such as TSP or TSS. This unsupervised approach is described in detail in the
“Methods” section of this chapter. The “Results” section provides a validation study of
using this method to investigate the molecular subtypes of breast cancer patients.
3.2 Methods
3.2.1 Pathway-based Top Scoring Set
The TSS method introduced in Chapter 2 provides an effective and transparent clas-
sification model based on gene expression levels. It explores the discriminative power of
the relative expression comparison in small-sized gene sets where subtle but consistent
expression changes of a few genes across all samples lead to class separation. However,
TSS is somewhat limited by the fact that it is not computationally feasible to carry out an
exhaustive search and the global optimality requirement needs to be relaxed. One way to
address this problem would be to pre-select a small number of genes based on a univariate
multiclass criterion such as one-way ANOVA. Another approach proposed in Chapter 2
is the greedy search algorithm. However, all these methods are exclusively based on the
expression patterns of genes, and the reliability of results derived in small-sample settings
could be questionable due to the inherent measurement noise in high-throughput data
and the heterogeneity across samples and patients. Motivated by these considerations,
this section introduces a new classification procedure that combines TSS with biological
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knowledge achieved from pathway analysis.
Pathways can provide biological interpretations while restrict attention to small-sized
(tens to hundreds) gene groups. For the TSS approach, each such group of genes offers
a unique opportunity to search for top scoring sets and to uncover subtle changes of co-
expression pattern in different phenotypes. In fact, the relative comparison idea used by
TSS could make more sense based on pathways where dependency structures among genes
are known to exist. Also, top scoring sets obtained by searching within pathways could
provide immediate biological insights into the underlying disease-related mechanisms.
Figure 3.1: Scheme of the pathway-based Top Scoring Set method.
The pathway-based TSS method is described in Figure 3.1. The procedure begins
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with a microarray gene expression data set and finds the functional modules defined by a
particular pathway database such as Gene Ontology or KEGG using the annotations of all
genes. Then, an optional step is to apply some enrichment technique to rank all pathways
according to their discriminative ability among different phenotypes, and pathways that
are identified as statistically significant are chosen. Next a complete search within each
of these pathways is performed to obtain high-scoring gene sets. Finally, the sets from
different pathways are compared to yield top scoring sets as the ultimate classification
rule.
The restriction to pathways greatly improves the efficiency of the search process. It
breaks down the large feature space into small groups of genes where relative expression
comparison is appropriate to consider within each group. These gene groups are pre-
defined using biological knowledge so that they can be more objective and meaningful
than those obtained by statistical hypothesis tests. Importantly, a pathway consists of
genes that connect and interact with each other, which can make the exploration of
relative expression analysis more promising than traditional methods.
The enrichment method used above requires multiclass analysis. In binary problems,
the celebrated GSEA method is the most common choice. In multiclass settings, there are
also a number of approaches that follow the similar procedures of GSEA and they differ
from each other in several aspects. First, the local statistic calculated for each gene in the
data can be different. The most common choice for this is the ANOVA F -statistic, and
the Kruskal-Wallis test statistic can also be an alternative. Second, the summary statistic
for each gene set can be different. Besides the Kolmogorov-Smirnov statistic considered
in GSEA, other metrics such as Wilcoxon rank sum (used in the SAFE method) can
also be reasonable options. Finally, the methods for assessing statistical significance of
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summary statistics can be different. The null distribution can be generated by permuting
class labels or creating bootstrap datasets.
In fact, as indicated in Figure 3.1, enrichment analysis is only optional since the
statistical significance of a pathway is not directly associated with the scores of gene
sets formed. In cases where there are a large number of pathways associated with genes
studied, enrichment methods can be introduced to filter out undesirable pathways that
contain noisy or no signals. However, the criterion of choosing significant pathways can
vary among problems and methods used, which may lead to totally different sets of
pathways selected. Therefore, for databases like KEGG where a relatively small number
of pathways (<300) is often identified, the enrichment analysis step is not necessary.
For some problems studied in this chapter, pathway-based TSS is applied in a similar
fashion to the k-TSP method introduced by Tan et al. [83]. To be precise, gene sets with
top k scores from the pathway search are combined to form the final classification rule.
For complex multicategorical diseases, the decision from a single gene set is unlikely to
be robust and effective, and it seems necessary to make ensemble decisions from a group
of high-scoring gene sets. In practice, a choice of the maximum number of gene sets
considered in the decision rule (denoted by kmax) is often specified. The optimal k(k ≤
kmax) is typically determined by using leave-one-out cross-validation (LOOCV) on the
training set, a common procedure for small-sized data [33,56]. However, LOOCV typically
requires extensive computations, especially for estimating the accuracy of a classification
method with parameters (e.g., the choice of k here). Therefore, the acceleration algorithm
described in Section 2.4.2 is also used to improve the efficiency of training such a pathway-
based k-TSS classifier. As discussed in Section 2.4.2, the acceleration algorithm can be
used for any collection of gene sets and can be immediately extended to select candidate
81
CHAPTER 3. PATHWAY-BASED CLASSIFICATION
gene sets for a k-TSS classifier. In particular, the acceleration algorithm used for the
pathway-based k-TSS classifier is described in Table 3.1.
Table 3.1: The acceleration algorithm for the pathway-based k-TSS classifier.
Acceleration Algorithm
Input: N training samples from m classes, a pre-defined pathway S and
kmax
Output: The reduced gene set list Ω.
1. Generate the collection of gene sets (size m) by considering all
possible combinations of genes from S. Denote the collection as
G = {g1, g2, ...}.
2. For each gene set gi ∈ G, compute the lower bound Lgi(n) and the
upper bound Ugi(n) under all possible situations that n training
samples are left out. Set n = 1 for leave-one-out cross-validation.
2. Rank all Lgi(n) in descending order and set L as the kmax-th largest
value of all Lgi(n), i = 1, 2, ...
3. Generate the list Ω consisting of all gi for which Ugi(n) ≥ L
Notations are the same as defined in Section 2.4.2. Note that multiple pathways can
also be considered by adding all possible gene sets (e.g., combinations of genes) from
these pathways to the collection of gene sets G. Also, the resulting gene set list Ω is used
in each iteration of the LOOCV process where top scoring sets are found among all gene
sets in Ω.
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3.2.2 Rank-based Clustering
Hierarchical clustering is one of the most popular techniques for microarray analysis.
It is often used to arrange samples according to similarity in patterns of expression.
The two basic building blocks in hierarchical clustering are the distance matrix and the
linkage method. The distance matrix consists of pairwise distances between samples to
be clustered. A number of sensible ways of defining the distance metric between two
samples can be used when samples have numerical-valued vectors associated with them,
including the Euclidean distance and the Pearson’s correlation coefficient. The linkage
method determines the distance between two groups of samples as a function of pairwise
distances. For example, the average linkage method defines the distance between two








i.e., the average of distances between any possible pair from A and B respectively. Based
on these two elements, hierarchical clustering uses the agglomerative algorithm to form
clusters in a bottom-up manner where two clusters with the smallest distance at each
step is merged. In general, hierarchical clustering has the distinct advantage that the
samples are not needed once the distance matrix is constructed.
In this section, a rank-based clustering approach is introduced for gene expression
analysis. In particular, the distance matrix associated with samples is calculated based
on relative ranks of gene expression levels and it is used in the hierarchical clustering
process. In the context of microarray analysis, value-based distance metrics such as the
Euclidean distance or the Pearson’s correlation coefficient rely entirely on the actual
expression values of the genes involved, which could be sensitive to subtle variations in
data preprocessing and the proportion of samples from each class. Hence, the goal here is
83
CHAPTER 3. PATHWAY-BASED CLASSIFICATION
to improve the robustness of hierarchical clustering by considering a rank-based distance
metric.
The rank correlation coefficient developed by Kendall [48] is an excellent choice for
the distance metric. This distance, sometimes referred to as the Kendall tau distance,
counts the number of pairwise disagreements between two ranking lists. The smaller
the distance, the more pairs of values remain the same relative ordering for two lists,
which indicates the two lists are more similar. The Kendall tau distance has already
been investigated by Afsari [1] for its use as a rank-based classifier for distinguishing
cancer phenotypes (See Section 2.5 in [1]). Here its potential for unsupervised clustering
is explored.
Now suppose an expression matrix {x(i)j } is given for i = 1, 2, ..., N samples and
j = 1, 2, ..., p genes. Samples are presumably from a number of phenotypes (e.g., tumor
subtypes), and genes are chosen so that they can be potentially related to phenotypes of





































Basically, d(i1, i2) measures the proportion of mismatches among a group of genes where a
mismatch is counted if a certain gene pair of sample i1 has a different maximum expressed
gene (i.e., gene whose expression level is the highest) from that of sample i2. In fact, this
distance could also be defined by considering mismatches of gene sets containing three,
four or any reasonable number of genes, but the computational complexity is expected
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to increase significantly.
By definition, if two samples have a small value of d(i1, i2), most of their two-gene
sets tend to have the same gene as the maximum expressed gene. As a result, they are
expected to have the same relative ordering for most two-gene sets. Also, it is quite
possible that the relative ordering of gene sets of larger sizes (>2) are also preserved. In
addition, a small d(i1, i2) also indicates a high probability that there exists a two-gene set
with the same maximum expressed gene across samples i1 and i2, which is related to the
idea of the TSP approach. When the mismatch is considered for gene sets of size greater
than two, the distance definition is related to the TSS approach.
A distance matrix D for N samples (and p genes) can be computed based on the
Kendall tau distance. Supervised classification rules can then be constructed based on
D. For instance, Afsari [1] considered the average swap distance as a classification rule








where nc is the number of samples in class c. Basically, the rule computes the average
Kendall tau distance between sample l and those in each class, and the prediction is the
class with the minimum average distance.
For unsupervised problems, the distance matrix D can be used in a similar way as for
supervised learning. The main assumption is that samples from different phenotypes are
expected to have larger distances than those from the same phenotype, which is intended
to indicate different genetic perturbations (e.g., activation of different pathways) existing
in the underlying mechanism of a certain disease. Based on the matrix D, hierarchical
cluster analysis can be immediately applied with a linkage method, and nothing else is
needed for clustering.
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The Kendall tau distance is a well-defined metric satisfying the following properties
for any samples i, j and k:
• d(i, j) ≥ 0 (non-negativity)
• d(i, j) = 0 ⇔ i = j (identity)
• d(i, j) = d(j, i) (symmetry)
• d(i, k) ≤ d(i, j) + d(j, k) (triangle inequality)
In addition, this distance can also be derived from the Hamming distance [39] that has
been frequently used in information theory.
In the following sections of this chapter, the pathway-based TSS classifier and the
rank-based clustering approach are validated in two settings. The first one is to distin-
guish subtypes based on an extremely large cohort study related to leukemia cancer. The
second one relates to the building of a subtype predictor for the prognosis of breast cancer
patients.
3.3 Results
3.3.1 Classification of Leukemia Subtypes
The study of leukemia cancer via gene expression analysis is the setting for one of
the earliest attempts in microarray-based cancer classification. In the prominent work by
Golub et al. [35], human acute leukemias were chosen as a test case where a microarray-
driven classification model was built based on 38 patient samples. The motivation came
from evidence showing that acute leukemias can be classified into those arising from lym-
phoid precursors (acute lymphoblastic leukemia, ALL) or from myeloid precursors (acute
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myeloid leukemia, AML), and no single test could efficiently establish the diagnosis. The
classification model derived included 50 informative genes and was tested on an indepen-
dent collection of 34 leukemia samples. 30 out of 34 samples were correctly predicted for
the ALL-AML distinction. Motivated by this work, the usefulness of microarray-based
gene expression classification has then been widely recognized and explored.
In this section, the first attempt was to test the pathway-based TSS (P-TSS) approach
on the same leukemia data from the Golub’s study using the same protocol for training
(38 samples) and testing (34 samples). Pathway information was collected from KEGG,
and the Bioconductor package [34] in R was used to find 226 KEGG pathways on the
data. To assess the statistical significance of these pathways, the GSA approach [25] was
used to perform enrichment analysis. Table 3.2 lists all differentially expressed pathways
identified by GSA when the false discovery rate (FDR) threshold is set to 0.2 and the
size (i.e., the number of genes) of a pathway is limited to between 15 and 500 by default.
A TSS classifier was built by searching within each of these five pathways, and it finally
contained five top scoring sets with the score of 2.94. The classification result on the
independent testing set was compared to that of benchmark classifiers in Table 3.3.
P-TSS achieves the highest accuracy, and it used the smallest number of genes. The
top scoring sets in the final decision rule come from two pathways, namely, primary im-
munodeficiency and hematopoietic cell lineage, both of which are statistically significant
with zero P value using GSA, and they also have interesting biological relevance. The
former one relates to disruption of the cellular immunity observed in patients with de-
fects in T cells or both T and B cells, and the latter one is linked to the manner in which
blood-cell development progresses from a hematopoietic stem cell.
While the result above demonstrates the effectiveness of P-TSS, due to small sample
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Table 3.2: Significant KEGG pathways identified on leukemia samples.
Gene set Size P value FDR
Primary immunodeficiency 32 < 0.001 < 0.001
T cell receptor signaling pathway 96 < 0.001 < 0.001
B cell receptor signaling pathway 68 < 0.001 < 0.001
Hematopoietic cell lineage 104 < 0.001 < 0.001
Rheumatoid arthritis 88 0.005 0.178
Table 3.3: Comparison of classification methods on leukemia samples.
Method Test error No. of genes







there is reason to anticipate a lack of robustness and reproducibility. To address this
issue, P-TSS was also tested on the microarray data from the MILE (Microarray Innova-
tions in Leukemia) study [37] described in Section 2.3.1, with the purpose of establishing
an accurate and robust class predictor. The large sample size and the strict data quality
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criteria utilized for MILE provides an excellent opportunity for validation. In particu-
lar, two classification problems (Table 3.4) were generated from the MILE data: one to
distinguish three major lineages (B-ALL, T-ALL and AML) in acute leukemia samples,
and the other to differentiate CLL (chronic lymphocytic leukemia), CML (chronic myel-
ogenous leukemia) and MDS (myelodysplastic syndromes). For these two large sample
problems, the k-TSS approach that makes ensemble decision based on the top k scoring
sets were used. The value of k with an upper bound of kmax = 50 was determined using
leave-one-out cross-validation (LOOCV) on the training set.
Table 3.4: Samples of leukemia subtypes used for classification.








For the first problem, the training began with a pathway analysis on all 1,457 (non-
missing) genes that are common for the training and test set. Information was collected
from KEGG database to yield 56 pathways, each of which was required to contain at least
10 members in order to obtain robust signals. Next, the k-TSS approach was applied by
searching within 56 pathways. The acceleration algorithm was used to generate a list of
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57 candidate gene sets, and the LOOCV accuracy for each k-TSS classifier (k ≤ kmax)
was estimated based on the list.



















Figure 3.2: LOOCV accuracies of all k-TSS classifiers on acute leukemia samples.
Figure 3.2 compares the LOOCV accuracy of k-TSS classifiers on 1,292 training sam-
ples. The optimal k was found to be 40 with the maximum LOOCV accuracy of 96.83%.
Therefore, a TSS classifier was built on the top 40 scoring sets in the training process.
Furthermore, an attempt was made to find the pathways in which these 40 gene sets were
formed. Interestingly, all 40 gene sets are actually from only two out of 56 pathways:
primary immunodeficiency and hematopoietic cell lineage. This result is remarkably con-
sistent with that obtained on the leukemia data from the Golub’s study where all top
scoring sets come from the same two pathways. Notice that this consistency is achieved
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on data sets from two different platforms (Affymetrix HuGeneFL and HG-U133 Plus 2.0),
which seems to indicate the biological importance of these pathways in the distinction of
three acute leukemia subtypes.
The second problem is to distinguish among two chronic leukemias (CLL, CML) and
MDS samples. Since the set of genes is the same as for acute leukemia samples, there are
still 56 KEGG associated pathways. In the training process, the acceleration algorithm
produced a list of 70 candidate gene sets and the LOOCV accuracies for all 50 k-TSS
classifiers are displayed in Figure 3.3. The optimal model turns out to be the 7-TSS
classifier with the highest accuracy of 97.26%. The top seven scoring sets are identified
from three pathways listed in Table 3.5.





















Figure 3.3: LOOCV accuracies of all k-TSS classifiers on chronic leukemias and myelodys-
plastic syndromes samples .
After training, the two k-TSS classifiers were tested on samples from stage II of the
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Table 3.5: Three KEGG pathways identified for chronic leukemias and myelodysplastic
syndromes samples.
Pathway Size No. of TSS Averaged score
Metabolic pathways 59 4 2.71
Pathways in cancer 47 1 2.67
Hematopoietic cell lineage 102 2 2.66
MILE study. In particular, two advanced machine learning techniques were selected
as benchmark methods: linear kernel support vector machines (l-SVM) and Prediction
Analysis of Microarray (PAM). The same implementation of these two methods as in the
“Classification of Human Cancer Microarray Data” section were used. Both benchmark
classifiers were optimized on the same training data through cross-validation, and the
fold was restricted to 10 to save computation time.
Validation results are provided in Table 3.6 and 3.7. For the first problem, P-TSS
achieves high accuracies, and the rate for B-ALL, T-ALL and AML is 98.0% and 93.7%
and 95.3% respectively. High accuracies are also observed for l-SVM and PAM. l-SVM
and PAM seems to outperform P-TSS in class AML, but are less effective in B-ALL.
P-TSS generally yields comparable accuracies to benchmark approaches, and it only uses
25 genes for classification while PAM uses 845 and l-SVM uses all 1457 genes. Moreover,
the decision rule for P-TSS is transparent and may be interpretable, which could have
some advantage over the complex decision boundaries generated by l-SVM and PAM.
Also, for the second problem, P-TSS obtains accuracies of 98.7%, 93% and 95.9%
for CLL, CML and MDS respectively. l-SVM turns out to be the best classifier on this
data with highest accuracies in all three classes. PAM also yields high accuracies in CLL
and CML, but for MDS accuracy is significantly lower than the other two methods. In
addition, l-SVM and PAM both uses all 1457 genes while only 21 genes are involved in
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Table 3.6: Confusion matrices on acute leukemias.
P-TSS
Actual ↓ / Predicted → B-ALL T-ALL AML
B-ALL 350 0 7
T-ALL 2 74 3
AML 3 9 245
l-SVM
Actual ↓ / Predicted → B-ALL T-ALL AML
B-ALL 347 2 8
T-ALL 2 74 3
AML 1 3 253
PAM
Actual ↓ / Predicted → B-ALL T-ALL AML
B-ALL 339 5 13
T-ALL 2 75 2
AML 1 7 249
the P-TSS classifier, and P-TSS again produces very comparable results.
Summary
The pathway-based TSS approach is proposed to search for top scoring sets whose
member genes are from the same pathway defined by a certain database. In this section,
this approach is trained and validated on two microarray data sets related to leukemia
cancer. The first one is a widely studied group of 72 leukemia patients. In this case, P-TSS
used only five gene sets from two KEGG pathways for classification and outperformed
all benchmark methods. The second one is from the MILE project, one of the largest
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Table 3.7: Confusion matrices on chronic leukemias and myelodysplastic syndromes.
P-TSS
Actual ↓ / Predicted → CLL CML MDS
CLL 234 1 2
CML 1 40 2
MDS 0 5 116
l-SVM
Actual ↓ / Predicted → CLL CML MDS
CLL 236 1 0
CML 0 43 0
MDS 3 1 117
PAM
Actual ↓ / Predicted → CLL CML MDS
CLL 236 0 1
CML 0 42 1
MDS 1 22 98
cohort studies of leukemia cancer. The top k scoring sets obtained by searching within
all available KEGG pathways were combined for an ensemble classification where k was
optimized on the training set by LOOCV. The effectiveness and robustness of P-TSS
were demonstrated on two data sets generated from the MILE study.
The results above show that the P-TSS classifier is reliable for classification of leukemia
subtypes. Previously, top scoring sets have been sought using all available genes, and one
possible issue is the over-fitting problem. Here, although each pathway typically contains
only tens to hundreds of genes, gene sets with high scores can still be found and have
been proved to be effective for predicting new samples. It is interesting that these gene
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sets may not come from pathways identified as statistical significant by any enrichment
method, which implies the difference between the traditional expression analysis and the
relative expression analysis.
Nonetheless, there are several limitations for results obtained in this section. One
limitation is the set of genes used for the MILE data. In fact, the training set from stage
I contains 54,675 genes, but only 1,457 genes that are shared by the validation set are
used in the training process. This fact significantly restricts the number of possible gene
sets that are formed from pathways. Also, since all expression data sets considered here
are related to leukemia cancer, it is desirable to have further study on other types of
diseases.
3.3.2 Breast Cancer Prognosis through Subtype Pre-
diction
Background
Microarray-based expression studies have uncovered that breast cancer is both a clin-
ically diverse and molecularly heterogeneous disease [38]. Although most treatment de-
cisions are still based on clinical-pathological factors such as age, tumor size, histological
grade, lymph node metastasis, estrogen receptor and progesterone receptor status, etc.,
molecular subtypes of breast cancer defined by distinct gene expression patterns have
been demonstrated by various research groups [65, 76, 77] to be associated with clinical
outcome. In the last decade, several statistical models have been proposed to identify
breast cancer subtypes at the molecular level where different subtypes tend to have differ-
ent risks of relapse/survival or responses to chemotherapy. Although the stability of these
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predictive models is still unclear and being tested, their concordance with respect to the
predictions for individual patients has been demonstrated by Fan et al. [28]. In addition,
a high rate of concordance has also been reported between the identified subtypes and
the risk classifications generated by well-known gene signatures such as Mammaprint [86],
Oncotype DX [61] and the Gene expression Grade Index (GGI) [78]. As a result, there
is an increasing need for the development of independently validated methods for the
identification of these subtypes.
According to the seminal work of Perou et al. [64], breast cancer tumors can be clas-
sified into at least four subclasses: luminal, basal-like, HER2-ennriched (HER2+) and
normal breast-like. This classification is based on a large set of “intrinsic” genes (i.e.,
genes exhibiting little variance within repeated samples of the same tumor while hav-
ing high variance across different tumors) and these classes have been termed “intrinsic”
subtypes. Some subsequent studies confirmed the identification of these subtypes and
showed that the luminal group could be further divided into two (luminal A and B) or
three (luminal A, B and C) subclasses. Also, Desmedt et al. [15] studied a number of
biological processes including estrogen receptor (ER) and HER2 signaling and derived a
slightly different classification of breast cancer tumors consisting of three main subtypes:
ER-/HER- (basal-like), HER2 (HER2+) and ER+/HER- (luminal) where luminal sub-
classes were combined into a single one and the normal breast-like group was left out.
The most commonly used technique for identifying molecular subtypes of breast cancer
is hierarchical clustering, which allows a simultaneous analysis of many genes for detect-
ing co-expressed groups. However, as discussed in [38], this approach requires samples in
large retrospective studies and can not be employed for identifying subtypes for samples
from individual patients. Therefore, several statistical models called “single sample pre-
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dictors”(SSPs) have been developed to assign the subtype of a single tumor. Although
these models have been based on different lists of intrinsic genes, their classification rules
are essentially of the nearest centroid classifier type that computes the “distance” between
a given sample and the centroid of each subtype based on expression values of intrinsic
genes, and selects the “nearest” subtype. In the latest derivation of SSP, the PAM50
model employed the nearest shrunken centroid approach PAM (introduced by Tibshirani
et al. [85]) and was based on only 50 genes.
Despite the considerable success achieved by SSP models, their limitations have been
showed and discussed in several studies. One major issue lies in the statistical methods
used for subtype identification and classification [38]. First, the clusters detected in
hierarchical clustering based on expression values are not stable under subtle variations
in data preprocessing as well as the choices of samples. Second, subtype classifications
have been reported to depend on the list of intrinsic genes [88], and different SSPs only
yielded moderately concordant classifications. Due to these limitations, some alternative
subtype models were also proposed that are not based on any intrinsic gene list such as
the Subtype Classification Model [38].
In this section, the ability of the rank-based clustering approach to independently
identify previously defined subtypes is investigated. The goal here is not to demonstrate
the superiority of this approach in terms of clustering or classification, but to validate
the possible existence of “intrisic” breast cancer subtypes and to provide one of many
explanations for the structural difference among these subtypes through the relative ex-
pression analysis. As discussed above, although breast cancer is commonly known to be
molecularly heterogeneous, the lack of “gold standard” classifications of breast cancer
subtypes largely limits the validation of various subtype classification methods/models.
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The study carried out in this section adopts one of the most notable lists of intrisic genes
used by the PAM50 model to explore the existence and the consistency of the previously
identified subtypes. At the same time, the k-TSP classifier is proposed for the prediction
of individual tumors based on the subtypes identified. Both the clustering and classi-
fication approach are compared to the PAM50 model using commonly used statistical
tests.
Gene Expression Data
A collection of three gene expression data sets (VDX, MAINZ and TRANSBIG) pro-
vided in [38] were used. These data sets were assayed on the same platform and they
contain 742 untreated and node negative patients with distant metastasis-free survival
data available. None of these data sets were used to derive the PAM50 model, but VDX
was used for training the rank-based clustering. k-TSP and PAM50 were applied on
MAINZ and TRANSBIG for subtype prediction and survival analysis. Other informa-
tion about these data sets is provided in Table 3.8.
Table 3.8: Three gene expression datasets of breast cancer patients.
Dataset Platform No. of genes No. of samples Source Reference
VDX Affymetrix HGU133A 22283 344 GSE2034/GSE5327 [87]
MAINZ Affymetrix HGU133A 22283 200 GSE11121 [73]
TRANSBIG Affymetrix HGU133A 22283 198 GSE7390 [16]
Subtype Discovery
The class discovery of breast cancer tumors is a major challenge to the development of
molecular subtype models. Hierarchical cluster analysis is often employed to handle this
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unsupervised learning task, but its biostatistical limitations and numerical instability have
been well documented [67]. For the prevalent SSP models, clustering results depend on
the list of intrinsic genes. Moreover, Mackay et al. [58] pointed out the lack of objectivity
and interobserver reproducibility in manually identifying subtypes from dendrograms
yielded by hierarchical clustering. As a result, there are no clear guidelines for describing
in detail how each molecular subtype should be identified from the visual analysis of the
dendrograms obtained from hierarchical cluster analysis.
Despite these difficulties, as recently discussed by Perou et al. [64], the intrinsic sub-
type model is an evolving classification system. PAM50 should be preferred over earlier
SSP models and its predictive power as well as prognostic value is likely to be confirmed
as more and more independent validation studies are carried out. Therefore, an attempt
has been made for discovery of breast cancer subtypes based on the intrinsic gene list
of PAM50 while using the rank-based hierarchical clustering. The rank-based approach
adopts a completely different methodology to define the distance metric, which makes
use of the relative ordering instead of the actual expression values of the intrinsic genes.
Two samples are defined as “close” to each other if their relative orderings match for
most possible gene pairs.
The list of 50 intrinsic genes used by PAM50 was obtained from the R package genefu.
Genes were mapped using Entrez GeneID. The probe with highest variance was used
when multiple probes mapped to the same GeneID. 44 out of 50 genes were found in the
probe set of three gene expression data in Table 3.8. A (rank-based) distance matrix was
constructed for 344 samples in VDX based on 44 genes. The average-linkage hierarchical
clustering was applied and the dendrogram was displayed in Figure 3.4.
At the highest level, the samples seemed to be clustered into four large groups. The
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Figure 3.4: Rank-based hierarchical clustering of breast cancer tumors.
leftmost group is separated from the other three with a distance of roughly 0.35. The
second group from the left is the smallest and is at least a distance 0.25 apart from the
two large groups on the right. The average distance in each group is around 0.15, which






matched between two samples from the same group. Previous studies have shown that
there are at least four breast cancer subtypes, so it is desirable to estimate the concordance
between the previously defined subtypes and the clusters found in Figure 3.4.
Figure 3.5 is colored using the five subtypes predicted by PAM50. All basal-like tumors
seemed to be included in the leftmost group, together with all normal-like tumors. All
expect one HER2+ tumor is in the second group (from the left). The next group contains
all luminal A tumors and the last one is a mixture of luminal A and B tumors. The five
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Figure 3.5: Rank-based hierarchical clustering of breast cancer tumors. Colors represent
subtypes predicted by PAM50: red - Luminal A, blue - Luminal B, green - basal-like,
magenta - HER2+, yellow - Normal.
subtypes of tumors are generally separated from each other where samples in the same
subtype tended to have smaller distances than those in different subtypes. The distinction
between luminal A and B tumors is not very clear and luminal B is the most scattered
group.
To quantitatively assess concordance between PAM50 predictions and the rank-based
clustering results, Cohen’s Kappa (κ) was used as implemented in the R package epibasix.
κ is a statistical measure of inter-rater agreement for categorical items and is thought to
be a more robust measure than simple percent agreement because it discounts the effect
of agreement by chance. κ ranges from 0 to 1 and typically has qualitative descriptions
about agreement associated with different intervals. One problem of using κ is that the it
assumes equal number of classes predicted by two methods for which the concordance is
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assessed, and there are only four clusters identified in Figure 3.5. However, as the normal-
like tumors are considered as an invalid subtype in some studies [38, 88], they have been
excluded in the concordance analysis. As a result, the predictions from PAM50 and the
rank-based clustering are summarized in Table 3.9.
Table 3.9: Subtype classifications by PAM50 and the rank-based clustering.
Cluster / Subtype Lum A Lum B Basal HER2+
1 94 0 0 0
2 38 89 0 0
3 0 2 80 1
4 2 12 0 15
The estimate of κ above is 0.766 (the simple percentage agreement is 0.835), which
suggests excellent agreement. Basal-like tumors are the most concordant subtype iden-
tified, and the least concordant distinction is between luminal A and B tumors. These
results confirm the findings of previous studies about the basal-like and luminal can-
cers [46]. The subdivision of luminal tumors has been reported to be strongly dependent
on the expression of proliferation-related genes that actually forms a continuum, and the
identification of subclasses is hence challenging.
Subtype Prediction and Survival Analysis
Hierarchical clustering can only be applied retrospectively on a collection of sam-
ples, and classification models need to be developed to produce predictions for individual
samples. Motivated by the rank-based clustering method, the k-TSP classifier is in-
troduced as a subtype predictor. In rank-based clustering, two samples from the same
cluster/class tend to have a relatively small distance and they generally possess a large
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number of “consistent” gene pairs (that is, two genes preserve their relative ordering
across these samples). As a result, the probability of having a “consistent” gene pair
turns out to be high for two samples with a small distance. Therefore, it is natural to
consider differentiating one class from another in the same way as the TSP classifier.
An attempt was made to build a subtype classifier using the clustering result on
VDX. For each cluster in Table 3.9, the subtypes with the most samples was chosen to
constitute the training set. In addition, 11 normal-like tumors contained in cluster 3 were
also selected. As a result, the training set contains 289 samples with 94 luminal A, 89
luminal B, 80 basal-like, 15 HER2+ and 11 normal-like tumors. The k-TSP classifier was
constructed with k ≤ 50, and the multiclass problem was handled by an ensemble of five
decision rules. To be precise, for a certain k, a list of top k scoring pairs was obtained
for distinguishing each subtype from all other groups. The aggregation of these five lists
formed the final decision rule. For predicting a sample, the number of “consistent” gene
pairs between the sample and each of the five lists was counted, and the predicted subtype
was taken to be the list having the most counts.
To find the optimal k, the re-substitution errors of different k-TSP classifiers were
assessed on the training set and compared in Figure 3.6. The misclassification rate was
used for the measure of error and the re-substitution error could be a good approximate
of the generalization error when sample size is large. A similar procedure was employed in
[59] for the model optimization of k-TSP. The minimum error was achieved by k = 48, 49
and 50. The 48-TSP classifier was chosen because it contained less genes in total.
The subtype classifier was tested on an independent validation set combining 398
samples from MAINZ and TRANSBIG (Table 3.8). There are 201 luminal A, 121 luminal
B, 57 basal, 11 HER2+ and 8 normal-like tumors predicted. This result is compared to
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Figure 3.6: Re-substitution errors of k-TSP classifiers.
the predictions of PAM50 in Table 3.10. Excellent agreement is observed between PAM50
and 48-TSP with κ = 0.779.
Table 3.10: Subtype predictions by PAM50 and the 48-TSP classifier.
48-TSP / PAM50 Lum A Lum B Basal HER2+ Normal
Lum A 183 9 0 0 9
Lum B 22 93 0 6 0
Basal 0 1 53 0 3
HER2+ 1 3 0 7 0
Normal 0 0 2 0 6
To analyze and compare the prognostic value of subtype predictions, Cox propor-
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tional hazard regression was considered. Subtypes were treated as categorical with no
assumption made on order across subtypes. Both univariate and multivariate analysis
were employed. In the multivariate model, the three available clinical-pathological vari-
ables, age, tumor size (>2cm vs. <2cm) and histological grade, were included. Distant
metastasis-free survival times were used as endpoints and censored at 10 years.
Table 3.11: Univariate Cox proportional hazards models of breast cancer patients.
Variables HR LR Log-rank score P value
Age 0.997 0.08 0.46 0.4955
Size 1.37 2.64 2.74 0.098
Grade 1.38 4.74 13.01 0.0003
48-TSP 20.45 27.05 0.0004
Luminal A 1 -




PAM50 21.9 23.17 0.0002
Luminal A 1 -




In the univariate analysis, the 48-TSP and PAM50 classifier are both found to be
significantly associated with distant metastasis-free survival. 48-TSP gives a lower likeli-
hood ratio but a higher log-rank test score. The luminal A versus luminal B segregation
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is found more significantly in PAM50 than for 48-TSP. The basal-like segregation for both
predictors have the same significance level. 48-TSP seems to have a better segregation for
normal-like tumors. The luminal A versus HER2+ segregation is not found significantly
by both classifiers. Besides the subtype variable, only histological grade appears to be
significantly associated with distant metastasis-free survival. In the multivariate result,
both predictors obtain a large increase of the likelihood ratio when adding the subtype
information to the variable group of age, tumor size and histological grade.
Survival curves were plotted using the Kaplan-Meier estimator and compared using
the log-rank test. The subtype distinctions in both curves are statistically significant,
which confirms the substantial prognostic value of breast cancer subtyping on early un-
treated patients. The prognosis of patients in both curves seem to be similar and are
almost consistent with risk classifications in previous studies [28]: lumina A tumors are
classified as low risk while luminal B, basal-like and HER2+ tumors are classified as high
risk. The abnormally high risk of the normal-like group is not observed previously and is
likely to be incorrect due to the small number identified. As mentioned before, the lumi-
nal B was better separated from luminal A by PAM50, but the segregation of basal-like
and HER2+ versus luminal A was better in predictions by 48-TSP.
Summary
The prognosis of breast cancer via subtype predictors has been extensively explored in
the last decade. A major family of methods are the SSPs based on lists of intrinsic genes.
While efforts have been made to reduce the number of intrinsic genes used from 500 to
50, the hierarchical cluster analysis employed by all SSPs has several limitations when
applied to gene expression data from different cohorts and microarray technologies. More
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Figure 3.7: Kaplan-Meier curves.
importantly, all SSPs adopt similar procedures to identify subtypes of breast cancer, the
results need to be validated by other independently developed methods. In the study of
Haibe-Kains et al. [38], the SSPs only yielded fair to moderate concordance with another
family of methods called Subtype Classification Models.
The rank-based clustering approach described in this chapter provides an independent
validation on a collection of three gene expression data sets of breast cancer patients.
This approach adopts the Kendall’s rank coefficient as the distance metric in hierarchical
cluster analysis, and can be robust against some commonly used preprocessing techniques
required for microarray data. In this chapter, the k-TSP classifier is proposed to predict
subtypes of individual samples as compared to the nearest centroid method used in SSPs.
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In particular, the prognostic value of early untreated patients is investigated.
The rank-based clustering approach on 344 breast cancer patients of VDX produced
four large clusters using 44 intrinsic genes. PAM50 predictions were used to identify the
subtype associated with each cluster. Basal-like tumors seem to be significantly different
in terms of relative orderings of genes and are all contained in one cluster. The segregation
of other subtypes is less significant, especially for luminal A and B tumors. The PAM50
predictions and the rank-based clustering results have obtained excellent concordance
with Cohen’s Kappa equal to 0.766. 289 samples in the same cluster and also predicted
by PAM50 as the same subtype were used to train a k-TSP classifier. The choice of k
was optimized on the training set using the re-substitution errors. The optimal 48-TSP
classifier was validated on 398 samples a combined gene expression data from MAINZ
and TRANSBIG study. In the survival analysis, the subtype predictions were found
significantly associated with distant metastasis-free survival. The significance level was
comparable to that of PAM50. The segregation of some survival curves (e.g., HER2+
versus luminal A) was even better than that of PAM50.
This study demonstrates the ability of the rank-based clustering approach for iden-
tifying breast cancer subtypes. Samples from different subtypes tend to have different
pairwise orderings, which can be a robust signal for distinguishing subtypes. The high
concordance with the subtypes identified by PAM50 provides an independent validation
for the existence of these intrinsic subtypes. Also, the predictive power of the k-TSP




4.1 Multiclass Relative Expression Analysis
This thesis is focused on the development of multiclass rank-based methodologies to
address the current limitations of applying statistical learning techniques on microarray
gene expression data. Methods are tailored to the realities (e.g., “small n, large p”) of the
available data and to the properties (e.g., multiclass, biological) of problems. The relative
expression orderings of small-sized gene sets are explored and modeled for microarray-
based diagnosis and prognosis of human diseases.
In Chapter 2, the Top Scoring Set method is developed for classification of multiclass
problems with respect to human diseases such as cancer. Specific m-gene sets named
“top scoring sets” are sought to distinguish m classes based on the relative comparison
of expression values. The underlying assumption is that the high expression level of a
certain gene relative to others in each top scoring set is strongly indicative of the sample
from a distinct class. The assumption leads to a transparent and potentially interpretable
decision rule that often involves a small collection of m-gene sets. But the search process
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for such gene sets turns out to be a main challenge. Univariate statistical tests (e.g.,
Wilcoxon rank sum, ANOVA) are commonly used for efficient dimension reduction, but
they are not best suited for the TSS classifier as well as the underlying biology of the
problem under study. As a result, the greedy search algorithm is proposed to pre-select
a collection of locally optimal gene sets in which the top scoring sets are sought. This
pre-selection process adopts an iterative procedure and enables a fast search among the
large feature space. In addition, ensemble classification is also investigated for the TSS
approach. Three ensemble methods (k-TSS, RF-TSS and SAMME-TSS) are introduced
and studied. In particular, k-TSS considers a majority rule based on the top k scoring
sets; RF-TSS uses a large collection of randomly formed gene sets and SAMME-TSS
adopts the SAMME algorithm, a multiclass extension of the Adaboost algorithm. The
methods proposed in this Chapter are validated on a number of gene expression data.
The greedy search-based TSS method are tested on seven disease classification problems
and the predictive performance is compared to that of five benchmark classifiers (kNN,
NB, RF, l-SVM and PAM). Moreover, it has been validated on an extremely large data
set from the MILE project and is compared to two different ensembles of support vector
machine classifiers. In both cases, comparable or even better results have been observed.
In addition, three ensemble approaches are validated on a large group of bladder cancer
patients from multiple locations. Both k-TSS and SAMME-TSS are found to improve
the performance of the TSS classifier.
In Chapter 3, the search process of the TSS classifier is further explored in the situation
that publicly available pathway databases can be introduced for biologically meaningful
dimension reduction. The formation of each gene set is restricted to contain only genes
from the same pathway defined by a certain database such as KEGG or Gene Ontology.
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The search efficiency is significantly improved due to the small sizes of pathways, and
the relative expression comparison can be more biological interpretable than that of
randomly formed gene sets. The k-TSS approach is proposed to construct an ensemble
classifier in which the decision is based on top k scoring sets sought within pathways, and
an acceleration algorithm is developed to improve the efficiency for optimizing k in the
training process. The pathway-based k-TSS approach is validated on two well-studied
microarray data sets. One is the group of acute leukemia samples from the Golub’s study
and the other is the large leukemia cohort from the MILE project. The effectiveness and
robustness of the pathway-based TSS classifier is demonstrated under both small and
large sample situation.
Chapter 3 also explores the ability of rank-based methods for unsupervised learning.
A rank-based clustering approach is considered by using hierarchical cluster analysis and
the Kendall’s rank coefficient as the distance metric. The metric is proportional to the
number of gene pairs that have the same relative ordering across two samples where
gene pairs are selected from a pre-defined group of genes (e.g., pathway). Compared to
the value-based metric such as the Pearson’s correlation or the Euclidean distance, this
rank-based metric can be more robust due to the use of relative ordering instead of the
actual expression values. This clustering approach aims to detect samples having similar
combinatorial behaviors in a group of genes, which can be a way to probe the dependency
structure in genetic networks. This technique is used to discover the intrinsic subtypes of
breast cancer tumors, and is compared to the subtypes predicted by the popular PAM50
model. The high concordance measured by Cohen’s Kappa is observed between subtypes
identified by two methods, which provides an independent validation for the existence
of these intrinsic subtypes. In addition, the k-TSP classifier is introduced for predicting
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subtypes of individual samples. The predictions of k-TSP and PAM50 on 398 early
untreated breast cancer patients are compared and analyzed. The high concordance is
again observed, and both models are found significantly associated with the times of
distant metastasis-free survival of patients.
4.2 Potential Future Work
The Top Scoring Set approach is one of the first attempts of using the relative ex-
pression analysis in multiclass problems. In binary microarray-based classification, the
TSP classifier has achieved considerable success using pairs of genes. The extension of
this rank-based method in the multiclass setting is difficult. The complexity of multi-
class classification is challenging for developing such rank-based method that can have a
transparent decision rule involving only a small number of genes. However, this thesis
demonstrates the predictive power existing in small-sized gene sets through relative ex-
pression comparison. The empirical distribution of such comparison seems to be one of
statistics that can be robustly estimated from the data available. Also, the exploration
of relative expression comparison is a practical attempt to study genetic interactions in
biological networks, which are well-recognized to be involved in complex diseases.
Considering gene sets with the “maximum” gene changing over classes is one of many
ways to investigate possible perturbations in genetic networks through expression relative
comparison. An immediate extension is to consider the same property with the “mini-
mum” gene for distinguishing classes. However, the “minimum” gene is often the gene
not being expressed and is not necessarily associated with the phenotypes under study,
which may not be used as a signal for classification. Although the work is not shown in
this thesis, an attempt has been made to search top scoring sets in terms of the “min-
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imum” gene and compare their predictive ability with those based on the “maximum”
gene. The results seem to be more favorable for the “max” version of the TSS classi-
fier. In addition, the number of complete orderings (permutations) of even a few genes
is large (e.g., 4!=24, 5!=120), and it is often impractical to estimate the distribution
of the complete orderings. TSS provides a way to combine some of these orderings to
gain statistical significance. As the sample size grows, more orderings can be considered
in the modeling process, which would give a more accurate estimate of the statistical
dependency structures among genes.
The investigation of the search process for top scoring sets is another focus in this
thesis. The greedy search algorithm provides a feasible way to efficiently search the
entire feature space for candidates of top scoring sets. But it is generally not efficient
enough on large data sets. The pathway-based search can be an excellent option for
dimension reduction. The KEGG database is used throughout this thesis to define gene
groups, but the use of other databases remains unexplored. One good alternative is to
use the Gene Ontology database that contains far more gene groups than KEGG. For
specific problems, some manually curated pathways can even be more valuable. Also, a
possible future goal is to develop a rank-based enrichment analysis that compares different
pathways according to their abilities of separating classes using the relative expression
analysis. In this situation, the pathways with genetic perturbations that cause a certain
disease are expected to be significantly associated with that disease.
The exploration of the rank-based clustering approach in Chapter 3 is far from com-
plete. The method has the limitation that a cluster detected in the dendrogram can not
be directly assigned to a well-defined subtype of breast cancer in previous studies. In fact,
as discussed in [58], this limitation of class discovery exists for all methods that use hier-
113
CHAPTER 4. DISCUSSION AND CONCLUSIONS
archical clustering, and it can cause disagreement of subtype identification. In this thesis,
only samples identified by both methods (the rank-based clustering and PAM50) as the
same subtype are used for training the subtype classifier. A potential future research is
to discover breast cancer subtypes directly from the clustering results with the aid of bi-
ological knowledge such as known genes or pathways associated with each subtype. Also,
the distance matrix used in the clustering process is based on the list of intrinsic genes in
PAM50. A possibly more objective approach would be to construct the distance matrix
using genes that are known to be involved in the progression of breast cancer tumors.
The subtype discovery process needs to be similar to that employed in [62,77] in order to
validate the rank-based clustering results. Once the subtypes are identified, the k-TSP
classifier can be trained and tested, and compared to popular subtype models such as
SSPs and SCMGENE.
At a higher level, the possible biological interpretation of relative expression compari-
son still needs to be validated, and the link between such comparison and the underlying
mechanism causing different phenotypes is not clear. A recent study [47] has shown the
effectiveness of such relative comparison based on expression levels of peptides and the
associated proteins for disease diagnosis. More future studies are expected for validat-
ing the use of gene expression microarray data, and for exploring the application of the
relative expression analysis to other types of data.
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